



HAL
open science

Design of P-Chirogenic Aminophosphine-Phosphinite (AMPP*) Ligands at both Phosphorus Centers: Origin of Enantioselectivities in Pd-Catalyzed Allylic Reactions

Antonin Jaillet, Christophe Darcel, Jérôme Bayardon, Adrien Schlachter, Christine Salomon, Yoann Rousselin, Pierre D Harvey, Sylvain Jugé

► To cite this version:

Antonin Jaillet, Christophe Darcel, Jérôme Bayardon, Adrien Schlachter, Christine Salomon, et al.. Design of P-Chirogenic Aminophosphine-Phosphinite (AMPP*) Ligands at both Phosphorus Centers: Origin of Enantioselectivities in Pd-Catalyzed Allylic Reactions. *Journal of Organic Chemistry*, 2020, 85 (22), pp.14391-14410. 10.1021/acs.joc.0c00536 . hal-02635117

HAL Id: hal-02635117

<https://univ-rennes.hal.science/hal-02635117>

Submitted on 28 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 Design of P-Chirogenic Aminophosphine-Phosphinite
2
3
4 (AMPP*) Ligands at both Phosphorus Centers: Origin of
5
6
7
8
9 Enantioselectivities in Pd-Catalyzed Allylic Reactions
10
11
12
13

14 *Antonin Jaillet,^{a§} Christophe Darcel,^b Jérôme Bayardon,^a Adrien Schlachter,^c Christine*

15
16
17 *Salomon,^{aδ} Yoann Rousselin,^a Pierre Harvey,^c and Sylvain Jugé^{*a}*
18
19
20
21
22
23
24
25

26 ^a Université de Bourgogne-Franche-Comté, Institut de Chimie Moléculaire (ICMUB-OCS,
27
28
29
30 UMR-CNRS 6302), BP 47870, 21078 Dijon Cedex, France
31
32
33

34 ^b Université de Rennes, Institut des Sciences Chimiques de Rennes (ISCR, UMR-CNRS
35
36
37
38 6626), 35000 Rennes, France
39
40
41

42 ^c Université de Sherbrooke, Département de Chimie, Sherbrooke, Québec, Canada
43
44
45

46 J1K2R1
47
48
49
50
51
52
53
54
55
56
57
58
59
60


RECEIVED DATE (to be automatically inserted after your manuscript is accepted if required according to the journal that you are submitting your paper to)

CORRESPONDING AUTHOR FOOTNOTE

[*] To whom correspondence should be addressed. -mail: sylvain.juge@u-bourgogne.fr,

Tel: +33 (0)3 80 39 61 13.

TABLE OF CONTENTS/ABSTRACT GRAPHIC



ABSTRACT

We have recently patented an unprecedented stereospecific $\text{N}\rightarrow\text{O}$ phosphinyl migration process which transforms P-chirogenic aminophosphines into phosphinites. A fine design of aminophosphine phosphinite ligands (AMPP*) derived from ephedrine and bearing a P-chirogenic center either at the aminophosphine or phosphinite moiety, was performed. The synthesis of AMPP* ligands with P-chirogenic aminophosphine moiety was based on the well-established stereospecific reaction of oxazaphospholidine-borane with organolithium

1 reagents, followed by trapping with a chlorophosphine and borane decomplexation.
2
3
4 Concurrently, the preparation of AMPP* ligands with P-chirogenic phosphinite moiety were
5
6
7 performed by N→O phosphinyl migration of aminophosphines borane by heating at 50 °C
8
9
10 with DABCO, and then reaction with chlorophosphines. AMPP* ligands were studied in
11
12
13 palladium-catalyzed asymmetric allylic alkylations, leading to enantioselectivities from 91%
14
15
16
17
18 (*R*) to 95% e.e. (*S*). X-ray crystallographic data for relevant Pd-AMPP* complexes and
19
20
21 computer modeling explained the origin of the enantioselectivities based on MO
22
23
24 interactions of most stable conformers with nucleophiles.
25
26
27

28 **KEYWORDS**

29
30
31 P-Chirogenic ligands / Asymmetric catalysis / Palladium / Allylic substitution /
32
33
34 Aminophosphine-phosphinites / Phosphorus rearrangement/ DFT-computation
35
36
37
38
39
40
41
42
43
44

45 **1. INTRODUCTION**

46
47
48 The chirality in phosphines used in enantioselective metal-catalyzed or
49
50
51 organocatalyzed reactions has overwhelmingly been located on the carbon skeleton.¹⁻³ If
52
53
54 the efficiency of P-chirogenic ligands is also documented,⁴ the design of chiral ligands at
55
56
57 the phosphorus centers has largely been neglected due to the lack of versatile methods to
58
59
60

1 efficiently design series of catalysts and to obtain their enantiopure stereoisomers.
2
3
4 Although the use of P-chirogenic compounds in organocatalyzed asymmetric reactions is
5
6
7 also known for several decades,³ their applications also recently increased significantly.⁵
8
9
10 Consequently and unsurprisingly, the design of P-chirogenic compounds (and not only
11
12
13 phosphines) is still a very active research area for the development of enantioselective
14
15
16 catalyzed reactions. So far, the stereoselective synthesis of P-chirogenic
17
18
19 organophosphorus compounds was usually achieved by P-C bond formation. This was
20
21
22 done using a limited number of P-chirogenic tetracoordinated building blocks, such as *t*-
23
24
25 butylmethylphosphine-borane, secondary phosphine-oxide or phosphinous-borane
26
27
28 derivatives.⁴
29
30
31
32
33
34

35 Chiral aminophosphine phosphinites (AMPP) such as **1-8**, represent a large family of
36
37
38 readily available bidentate ligands in asymmetric catalysis (Chart 1).⁶ These ligands are
39
40
41 obtained from the reaction between two equivalents of Ph₂PCI or (*c*-pent)₂PCI with
42
43
44 commercially available amino alcohols such as ephedrine, threoninol,^{7a} prolinol,^{7b} valinol,^{7c}
45
46
47 propranolol,^{7d} 1,2-diphenyl aminoethanol,^{7e,f} 2-indoline-methanol^{7g,h} or
48
49
50 azabicyclo[2.2.1]hept-3-ylmethanol.⁷ⁱ AMPP ligands **2-8** are excellent for the asymmetric
51
52
53 hydrovinylation of cyclohexadiene,^{7a} [2+2+2] cycloaddition,^{7b,c} hydrogenation of C=C^{7d-f,i} or
54
55
56
57
58
59
60

C=O,^{7g,h} respectively. Enantioselectivities up to 99% e.e. using Ni-, Co- or Rh-based complexes have been reached.





Chart 1. Representative Chiral Aminophosphine-Phosphinite (AMPP) ligands

The EPHOS ligand **1** derived from (-)-ephedrine, described in pioneering works by B. Petit and G. Buono,^{8a} led to moderate enantioselectivities in asymmetric hydrogenation,^{8b} hydroformylation,^{8c,d} hydrosilylation^{8e} and allylation^{8f} catalyzed by Pt-, Rh- or Pd-complexes, respectively. During the past decade, we and Vogt group have independently described the synthesis of two series of modified EPHOS ligands **13** and **16** with P-chirogenic phosphorus centers (Scheme 1).^{9,10}

Scheme 1. Stereoselective Synthesis of Modified EPHOS with P-chirogenic P-Centers



24 So far, a large series of P-chirogenic modified EPHOS ligands **13** (AMPP*) has been
 25 synthesized from the oxazaphospholidine-borane (-)- or (+)-**10**. They were derived from
 26 (+)- or (-)-ephedrine **9** based on a well-established methodology (Scheme 1).^{9,10} Thus, the
 27 borane complex (-)-**10** reacted with organolithium reagents (R¹Li) to afford the lithium salts
 28 [**11**] by a ring opening reaction upon P-O bond cleavage. The salts [**11**] were successively
 29 trapped with a chlorophosphine R²₂PCI then with borane to produce the AMPP*-diborane
 30 complexes **12**, and then isolated as air-stable and storable compounds (Scheme 1a). The
 31 free AMPP* **13** finally obtained after borane decomplexation of their corresponding
 32 diborane complexes **12** with DABCO, yielded up to 73% from ephedrine (Scheme 1a). This
 33 methodology permitted to synthesize numerous P-chirogenic AMPP* ligands **13** with R¹ =
 34 alkyl, cycloalkyl, aryl, bisaryl, heteroaryl or ferrocenyl and R' = phenyl-, α -naphthyl- or 3,5-
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

xylyl-substituents on the aminophosphine and phosphinite moieties, respectively (Scheme 1a).^{9,10} Similarly, the AMPP* ligands **13u-w** bearing *o*-biphenyl, calix[4]arenyl and 1,1'-binaphth-2-yl substituents on the P-chirogenic aminophosphine moiety were prepared using the same methodology, but starting from (-)-ephedrine **9** (Scheme 2 and Supporting Information, SI).^{9c} For instance of their efficiency in asymmetric catalysis, the rhodium(I) complex with the P-chirogenic AMPP* **13a** ligand bearing an *o*-anisyl group on the aminophosphine moiety (*i.e.* R¹ = *o*-An), efficiently promoted the asymmetric hydrogenation of dehydrophenylalanine with 99% e.e.^{9a} When the ring opened products **[11]** reacted with P-chirogenic chlorophosphine-boranes **14**, the resulting AMPP*-diboranes **15** were obtained with inversion of configuration at the phosphorus atom. After decomplexation by DABCO, the free P-chirogenic ligands **16** were diastereoselectively obtained with the chirality located on either the phosphinite or both aminophosphine and phosphinite moieties (Scheme 1b).^{9a,b}

However, the design of the phosphinite moiety in AMPP* **16** based on this methodology is limited. This is because the reaction of the products **[11]** with P-chirogenic chlorophosphine-boranes **14** bearing other substituents R², R³ than *o*-anisyl, phenyl or methyl group was proven to be difficult (Scheme 1b). In this case, the reaction of the secondary alkoxide salts **[11]** with the chlorophosphine-boranes **14** led to epimeric AMPP*

1 mixtures **16** with low yields due to the poor reactivity and the racemization of **14** in the
2
3
4 medium (Scheme 1b).¹¹
5
6

7 We have recently discovered an unexpected stereospecific intramolecular rearrangement
8
9
10 of free P(III)-chirogenic aminophosphine {R¹R²PN(R)-OH} derived from chiral 1,2-
11
12 aminoalcohols into their corresponding phosphinites {R¹R²PO-NH(R)}.¹² This
13
14 rearrangement obtained by stereospecific N→O phosphinyl migration, has been used for
15
16
17
18
19
20
21 the synthesis of AMPP* ligands **20** bearing a P-chirogenic phosphinite moiety. As proof of
22
23
24
25 the method efficiency, the stereoselective synthesis of four epimers of the *o*-biphenyl
26
27
28 containing AMPP* ligands **13f,i** and **20f,i**, was herein reported with (*R*_p)- or (*S*_p)-
29
30
31 configuration either on aminophosphine or phosphinite moieties. Finally, the P-chirogenic
32
33
34
35 AMPP* ligands **13** and **20** has been investigated in asymmetric palladium-catalyzed allylic
36
37
38
39 reactions and the resulting enantioselectivities (*R* or *S*), based on the P-chirality in the
40
41
42 metal-sphere of coordination, were explained by DFT computations.
43
44
45
46


47 2. RESULTS AND DISCUSSION

48
49
50
51 Due to the atropisomery of the binaphthyl substituent, the preparation of the AMPP* **13v**
52
53 warrants a particular attention (Scheme 2). The synthesis was achieved by reacting
54
55
56
57
58 oxazaphospholidine-borane (+)-**10a** (prepared from (-)-ephedrine) with the 1,1'-binaphth-2-
59
60

yllithium reagent (prepared by a metal-halide exchange of (\pm)-2-bromobinaphtyl **17** with *t*-BuLi), at -78°C in THF (Scheme 2). The aminophosphine-borane **11v** was obtained in 38% yield as a mixture of stereoisomers in 85:15 ratio. The major isomer of **11v** was isolated by crystallisation in ethyl acetate and its structure was established by X-ray diffraction. This latter showed that the absolute configuration at the phosphorus center was S_p when the atropisomeric binaphtyl moiety was M (see SI). The diastereoselectivity was explained by the dynamic resolution of the binaphtyllithium reagent during the reaction with the oxazaphospholidine-borane (+)-**10a** leading to the ring-opened product **11v** (Scheme 2).¹³


The aminophosphine-borane (M,S_p)-**11v** was then deprotonated with *n*-BuLi at -78°C , to afford the corresponding alkoxide salt [**11v**] which was trapped with Ph_2PCl then with borane to form the AMPP*-diborane complex **12v** in 41% yield. The free diastereomerically pure AMPP* (M,S_p)-**13v** was isolated in 85% yield after decomplexation of the diborane complex **12v** upon heating with DABCO in toluene at 50°C overnight, and purification on a neutral alumina column.

Scheme 2. Synthesis of P-chirogenic binaphtyl-AMPP* (M,S_p)-**13v**



1
2
3
4 Concurrently, the synthesis of AMPP* derivatives with the chirality located on the
5
6
7 phosphinite moiety was achieved according to Scheme 3. The aminophosphine-boranes
8
9
10
11 **11**, resulting from the hydrolysis of their alkoxide salts [11], afforded the P-chirogenic
12
13
14 aminophosphines **18** upon heating at 50°C in toluene overnight with two equivalents of
15
16
17 DABCO. The aminophosphine **18** then led to the P-chirogenic phosphinite **19** by
18
19
20 intramolecular S_N2 -like substitution resulting in N→O phosphinyl migration.¹² This new
21
22
23 rearrangement could also be achieved with 0.5 equivalent of DABCO. It proceeded with
24
25
26 complete retention of configuration at the P-atom and was easily monitored by ³¹P NMR.
27
28
29 The decomplexation of the aminophosphine-borane complex **11** into free aminophosphine
30
31
32 **18**, followed by the rearrangement into their corresponding phosphinites **19**, exhibited the
33
34
35 disappearance and appearance of characteristic signals at $\approx +70$, 50 and 110 ppm,
36
37
38 respectively (Scheme 3).
39
40
41
42
43
44

45
46 **Scheme 3. Synthesis of AMPP*s from Aminophosphines via N→O Phosphinyl Migration**



The phosphinites **19** could be isolated either under a P-free form or after complexation with borane. They were directly used without purification for the synthesis of the AMPP* **20** bearing a P-chirogenic phosphinite moiety. They reacted with the chlorodiphenylphosphine in presence of triethylamine at room temperature (Scheme 3). The free AMPP* ligands **20** were isolated from the reaction medium, but they were usually complexed by borane-dimethylsulfide and then stored as diborane complexes **21** (Scheme 3). The P-chirogenic AMPP* **20** were obtained as free ligands directly usable in asymmetric catalysis, in contrast with the synthetic method reported in Scheme 1. AMPP* **20**, their ^{31}P NMR chemical shifts and their diborane complexes **21**, are reported in Table 1.

Table 1. Synthesis of AMPP* and Diborane Complexes with P-chirogenic Phosphinite Moieties

	20a-i	(<i>S_P</i>)-20a,b	21a-i	(<i>S_P</i>)-21a,b
entry	ephedrine 9	AMPP* 20 R'1	AMPP*(BH ₃) ₂ ^a R	AMPP*(BH ₃) ₂ ^a R'21

		$\delta^{31}\text{P}^b$					yield	
							(%) ^c	
1	(+)	(<i>R</i> _p)-20a	<i>o</i> -An	Ph	Ph	+64.4	(<i>R</i> _p)-21a	68
						+100.5		
2	(-)	(<i>S</i> _p)-20a	<i>o</i> -An	"	"	+64.9	(<i>S</i> _p)-21a	65
						+100.1		
3	(+)	(<i>R</i> _p)-20b	α -Np	"	"	+65.0	(<i>R</i> _p)-21b	63
						+107.1		
4	(-)	(<i>S</i> _p)-20b	α -Np	"	"	+64.7	(<i>S</i> _p)-21b	61
						+107.4		
5	(+)	(<i>R</i> _p)-20c	β -Np	"	"	+64.8	(<i>R</i> _p)-21c	81
						+110.5		
6	(+)	(<i>R</i> _p)-20d	<i>o</i> -Tol	"	"	+64.7	(<i>R</i> _p)-21d	65
						+104.7		
7	(+)	(<i>R</i> _p)-20e	<i>p</i> -Tol	"	"	+64.5	(<i>R</i> _p)-21e	67
						+112.5		
8	(+)	(<i>R</i> _p)-20f	<i>o</i> -biPh	"	"	+64.9	(<i>R</i> _p)-21f	67
						+101.9		
9	(+)	(<i>R</i> _p)-20g	Fc	"	"	+64.7	(<i>R</i> _p)-21g	68
						+105.5		
10	(+)	(<i>S</i> _p)-20h	<i>t</i> -Bu	"	"	+66.4	(<i>S</i> _p)-21h	59
						+129.4		
11	(+)	(<i>S</i> _p)-20i	Ph	<i>o</i> -biPh	"	+65.1	(<i>S</i> _p)-21i	58
						+104.8		

^a Isolated yield from aminophosphine-borane **11**. ^b δ in ppm. ^c Diastereoselectivity (> 99%) checked by NMR.

The *o*-anisyl-aminophosphine-borane **11a** ($R^1 = o\text{-An}$, $R = \text{Ph}$), prepared from (+)-ephedrine, afforded the *o*-anisylphosphinite **19a** upon heating at 50°C overnight with two equivalents of DABCO in toluene. It reacted with Ph_2PCI in presence of NEt_3 to provide the free AMPP* (*R*_p)-20a (Table 1, entry 1). The AMPP* (*S*_p)-20a was similarly synthesized


1 from (-)-ephedrine **9** (entry 2). These AMPP* were characterized by their ³¹P NMR
2
3
4 chemical shifts at ~ +64 and +100 ppm, corresponding to their trivalent aminophosphine
5
6
7 and phosphinite moieties. They were isolated after addition of BH₃.DMS as diborane
8
9
10 complexes (*R_p*)- or (*S_p*)-**21a** in 68 or 65% yield, respectively (entries 1, 2). The
11
12
13 diastereoselectivity (> 99%) was checked by NMR analysis of the free AMPP* **20a** and its
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
diborane complex **21a**. The free P-chirogenic ligands **20a** could be recovered by borane
decomplexation of **21a** with DABCO (Scheme 3). In addition, the *α*- or *β*-naphthyl-, *o*- or *p*-
tolyl-, *o*-biphenyl-, ferrocenyl- and *t*-butylphenylphosphinites **19b-i** were obtained from the
rearrangement of their corresponding aminophosphine-boranes **11b-i** previously prepared
from (+)-ephedrine **9**. Finally, the reaction of the phosphinite-boranes **19b-i** with Ph₂PCI in
presence of NEt₃ and then complexation with BH₃.DMS, led to the AMPP*-diborane
complexes **21b-i** in yields up to 81% (entries 3-11).

The X-ray crystal structures of eight AMPP*-diborane complexes **21a-h** have been
solved. Their absolute configurations are reported in SI (Figures S8 to S16). Consequently,
as the borane complexation and decomplexation proceed with retention of configuration at
the P-atom, the resulting stereochemistry of the AMPP* **20** from aminophosphine-borane
11 is consistent with the retention during the N→O phosphinyl migration step (Scheme 3).
The ORTEP views of all AMPP*-diborane complexes **12**, **15** or **21** exhibited similar aspects

of unfolded conformations of the chain, flattened geometries for the amino groups, and *anti* orientation of the P–B bonds with P1-B1-P2-B2 dihedral angles up to 165° (Figures S4 to S16, SI).

The efficiency of the method was demonstrated by the stereoselective synthesis of all (*R_p*)- and (*S_p*)-epimers of the free *o*-biphenyl-containing AMPP* ligands **13f,i** and **20f,i**, bearing a P-chirogenic center either at the aminophosphine or phosphinite moiety. These epimers were prepared from the oxazaphospholidine-borane complexes (-)-**10a** and (-)-**10b** derived from (+)-ephedrine **9** (Scheme 4). The latter complex (-)-**10b** was prepared in a diastereomerically pure form according to a modified literature procedure.^{14,15} It uses successive reactions of (+)-ephedrine **9** with PCl₃, then with *o*-biphenyllithium reagent and finally with BH₃·DMS for complexation (Scheme 4).


Scheme 4. Diastereodivergent Synthesis of P-chirogenic AMPP* bearing an *o*-biphenyl Group



1
2
3
4 Oxazaphospholidine complex (+)-**10a** reaction with the *o*-biphenyllithium reagent led first
5
6
7
8 to the (*R*_p)-aminophosphine-borane **11f** in 81% yield (Scheme 4). This latter was reacted
9
10
11 with Ph₂PCI either directly followed by decomplexation, or after rearrangement upon
12
13
14 heating with DABCO to afford the free P-chirogenic AMPP* (*R*_p)-**13f** or (*R*_p)-**20f** in 40% and
15
16
17 67% yields, respectively (Scheme 4a,b). The X-ray structures of the diborane complexes
18
19
20
21 (*R*_p)-**12f** and (*R*_p)-**21f** of the AMPP* (*R*_p)-**13f** and (*R*_p)-**20f**, are showed in Figures S4 and
22
23
24
25 S14 (SI). Concurrently, the oxazaphospholidine complex (-)-**10b** reacted with the
26
27
28 phenyllithium reagent to form the (*S*_p)-aminophosphine-borane **11i** with a yield of 87%
29
30
31 (Scheme 4). The reaction of **11i** with Ph₂PCI followed by decomplexation, or after
32
33
34 rearrangement upon heating with DABCO, led to the free AMPP* (*S*_p)-**13i** and (*S*_p)-**20i** with
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
60
respective yield of 44% and 58% (Scheme 4c,d). Figure S6 (SI) shows the X-ray structure
of the borane complexes (*S*_p)-**12i** of P-chirogenic AMPP* (*S*_p)-**13i**, bearing an epimeric *o*-
biphenyl-aminophosphine moiety in relation to (*R*_p)-**13f**.

The P-chirogenic AMPP* ligands bearing P-chirogenic aminophosphine **13** or
phosphinite moieties **20** were studied in palladium-catalyzed allylic reactions of dimethyl
malonate and benzylamine (*vide infra*). The palladium-catalyzed asymmetric allylic

1 alkylation led to many elegant applications in organic synthesis and the fine design of
2
3
4 efficient chiral ligands is still topical.^{16,17} This asymmetric catalysis proceeds by nucleophilic
5
6
7 attacks to the π -allylic moiety formed upon complexation to palladium, which led Trost
8
9
10 group to develop efficient pocket-shaped ligands supported by a chiral 1,2-diamine
11
12
13 bridge.¹⁶ Although P-chirogenic ligands, such as **22** to **26**, led also to highly
14
15
16
17 enantioselective allylic catalyzed allylation with e.e. > 95%,¹⁸⁻²² the design of phosphines at
18
19
20
21 the P-centers for this reaction was rarely performed and few structural elements allowed
22
23
24
25 the prediction of their stereoselectivity (Chart 2). This outcome could be explained by a
26
27
28 limited level of understanding of the influence of chirality located on the P-atoms on the
29
30
31 environment of the π -allylic moiety. Given the homochirality of the twenty nine P-chirogenic
32
33
34
35 AMPP* **13** and **20** synthesized herein, they were investigated in Pd-catalyzed allylic
36
37
38 alkylation reactions. This was to determine the relationship between their structure and the
39
40
41 enantioselectivity (*R*) or (*S*) obtained.
42
43
44





53 **Chart 2. Representative P-chirogenic Phosphorus Ligands used in Pd-catalyzed Asymmetric**
54 **Allylic Alkylation**
55

1 The allylation reaction of dimethyl malonate was first examined with the allylic
2
3 substrate **27**, using 1-2 mol% of $[\text{Pd}(\text{C}_3\text{H}_5)\text{Cl}]_2$ and 2-4 mol% of AMPP* **13** or **21** as *in situ*
4
5 generated catalyst, in the presence of 2 equiv. of *N,O*-bis(trimethylsilyl)acetamide (BSA) in
6
7 dichloromethane, and a catalytic amount of potassium acetate as base (Tables 2 and 3).
8
9
10 According to the AMPP* used, the reactions were usually completed within 1 to 48 h at
11
12 room temperature to afford the mono allylated malonate **28**, in isolated yields up to 92%
13
14 (Table 2). The dependence of the reaction conditions on the allylation showed a moderate
15
16 effect on the enantioselectivity (see SI).
17
18
19
20
21
22
23
24
25
26
27

28 The catalyzed allylic substitution of the (*E*)-1,3-diphenylprop-2-en-1-yl acetate **27** by
29
30 palladium AMPP* complexes, was also investigated using benzylamine as the nucleophile.
31
32
33 The reactions were performed at room temperature in dichloromethane, using TBAF as
34
35 base, affording the corresponding allylated benzylamine **29** in 7 h. The results on the
36
37 catalyzed asymmetric allylations using the P-chirogenic AMPP* **13** and **21** are respectively
38
39 summarized in Tables 2 and 3.
40
41
42
43
44
45
46
47
48
49

50
51 **Table 2. Asymmetric Allylation of Dimethylmalonate and Benzylamine Catalyzed by**
52
53 **Palladium Complexes of AMPP*13**
54
55
56
57
58
59
60



entry	P-chirogenic AMPP* ligand 13	R ¹			product 28			product 29		
		R	R'	Yield (%) ^a	ee (%) ^c	abs. conf. (%) ^{a,d}	Yield (%) ^a	ee (%) ^c	abs. conf. (%) ^{a,d}	
1	EPHOS 1	Ph	Ph	Ph	-	42 ^e	(<i>S</i>)	90	27	(<i>R</i>)
2	(<i>R</i> _p)-13a	<i>o</i> -An	Ph	Ph	90	62	"	86	33	"
3	(<i>R</i> _p)-13b	<i>α</i> -Np	"	"	87	44	"	- ^f	-	-
4	(<i>R</i> _p)-13c	<i>β</i> -Np	"	"	74	38	"	"	"	"
5	(<i>R</i> _p)-13f	<i>o</i> -biPh	"	"	92	82	"	89	80	(<i>R</i>)
6	(<i>R</i> _p)-13g	Fc	"	"	83	70	"	91	56	(<i>R</i>)
7	(<i>S</i> _p)-13h	<i>t</i> -Bu	"	"	83	41	(<i>R</i>)	-	-	-
8	(<i>S</i> _p)-13i	Ph	<i>o</i> -biPh	"	91	91	(<i>R</i>)	89	95	(<i>S</i>)
9	(<i>S</i> _p)-13j	Me	"	"	88	41	(<i>S</i>)	- ^f	-	-
10	(<i>S</i> _p)-13k	<i>o</i> -Hex	"	"	66	61	"	"	"	"
11	(<i>R</i> _p)-13l	<i>o</i> -MEMPh	"	"	86	55	"	"	"	"
12	(<i>R</i> _p)-13m	<i>o</i> - <i>i</i> PrOPh	"	"	70	36	"	"	"	"
13	(<i>R</i> _p)-13n	<i>o</i> -BnOPh	"	"	70	34	"	"	"	"
14	(<i>R</i> _p)-13o	3,5-Xyl	"	"	74	8	"	"	"	"
15	(<i>R</i> _p)-13p	3,5-di(<i>t</i> -Bu)Ph	"	"	82	38	"	"	"	"
16	(<i>R</i> _p)-13q	3,5-di(<i>t</i> -Bu)-4-MeOPh	"	"	74	39	"	"	"	"
17	(<i>R</i> _p)-13r	2-Pyr	"	"	71	43	"	"	"	"
18	(<i>R</i> _p)-13s	2-(2',6'-diMeO)biPh	"	"	86	28	(<i>R</i>)	"	"	"
19	(<i>R</i> _p)-13t	<i>o</i> -biPh	"	<i>α</i> -Np	82	70	"	"	"	"
20	(<i>S</i> _p)-13u ^g	Calix	"	Ph	87	27	"	"	"	"
21	(<i>M,S</i> _p)-13v ^g	2-biNp	"	Ph	84	81	"	"	"	"
22	(<i>S</i> _p)-13w ^g	<i>o</i> -biPh	"	3,5-Xyl	84	85	"	"	"	"

^a Reactions were carried out in CH₂Cl₂ ([**27**] = 0.3 M) with 1-2 mol% of [Pd(C₃H₅)Cl]₂ and 2-4 mol% of AMPP* **13**, 2 equiv. of dimethyl malonate or benzylamine as nucleophile, 2 equiv. of *N,O*-bis(trimethylsilyl)acetamide (BSA) and a catalytic amount of KOAc (10 mol%) or 2 equiv. of TBAF as base, respectively. ^b The reaction was performed to completion in 1 to 48 h. ^c Determined by HPLC on chiral column. ^d Reaction time 7 h. ^e Reference 8f. ^f Test not realized. ^g Prepared from (-)-ephedrine **9**.

EPHOS ligand **1** (R¹, R, R' = Ph) bearing achiral aminophosphine and phosphinite moieties used in the Pd-catalyzed asymmetric allylation of malonate and benzylamine, exhibited moderate enantioselectivities of 42%^{8f} and 27% e.e. for products (*S*)-**28** and (*R*)-**29**, respectively (Table 2, entry 1). In contrast, the enantioselectivities of the catalyzed reactions exhibited a strong substituent-dependence of the P-chirogenic EPHOS ligands **13**, as the allylated products **28** and **29** with (*S*)- or (*R*)-configurations were obtained with enantioselectivities up to 95% (entry 8). However, when the AMPP* ligands **13** derived from (+)-ephedrine bore R¹ = *o*-An, α -Np, β -Np, Fc, Me, *c*-Hex, *o*-MEMPh, *o*-*i*PrOPh, *o*-BnOPh, 3,5-Xyl, 3,5-di(*t*Bu)Ph, 3,5-di(*t*Bu)-4-MeOPh or 2-Pyr on the aminophosphine moiety, the allylated methyl malonate (*S*)-**28** were obtained with 8-70% e.e. (entries 2-4, 6, 9-17). In the case of AMPP* **13u** linked at the upper-rim to a calix[4]arene unit, the catalyzed allylic alkylation also led to a low enantioselectivity (27% e.e.; entry 20). On the



1 other hand, when the catalyzed allylation was performed with the AMPP* **13h** or **13s**
2
3 prepared from (+)-ephedrine **9** and bearing *t*-butyl or 2-(2',6'-dimethoxy)biphenyl as R¹
4
5
6
7 substituent, the observed enantioselectivities were reversed and (*R*)-**28** was obtained with
8
9
10 41 and 28% e.e., respectively (entries 7, 18). When the aminophosphine arm of the AMPP*
11
12
13 ligands **13** bore a binaphthyl or a biphenyl substituent, the enantioselectivities were strikingly
14
15 enhanced. Thus, the binaphthyl AMPP* (*M,S_p*)-**13v**, derived from (-)-ephedrine **9**, was used
16
17
18 in the palladium-catalyzed asymmetric allylation of the dimethyl malonate, the product (*R*)-
19
20
21
22 **28** was obtained with 81% e.e. (entry 21). Using the ligand AMPP* **13f** derived from (+)-
23
24
25 ephedrine **9** and bearing an *o*-biphenyl as R¹ substituent, the palladium catalysed reaction
26
27
28 afforded the allylated malonate derivative (*S*)-**28** with 82% e.e. (entry 5). Surprisingly,
29
30
31 when the phenyl- of diphenylphosphinite moiety of AMPP* **13f** was replaced by a α -
32
33
34 naphthyl- or a 3,5-xylyl- group, the corresponding AMPP* **13t** and **13w** exhibited a modest
35
36
37 change of the enantioselectivities. This was because the asymmetric catalyzed allylation
38
39
40 were achieved with 70% and 85% *vs* 82% e.e., respectively (entries 5, 19 and 22).
41
42
43 Interestingly, the AMPP* (*S_p*)-**13i** derived from (+)-ephedrine **9** and bearing an *o*-biphenyl
44
45
46 substituent at the aminophosphine moiety as R group, led to the allylated product (*R*)-**28**
47
48
49 with 91% e.e. (entry 8). In this latter case, the product **28** was obtained with a reversed
50
51
52 absolute configuration upon using the epimeric *o*-biphenyl AMPP* ligand (*R_p*)-**13f**. This
53
54
55
56
57
58
59
60

illustrates the key importance of the P-chirality at the aminophosphine moiety on the enantioselectivity of the catalytic transformation (82% e.e. (*S*) vs 91% e.e. (*R*); entries 5 and 8).²³

The AMPP* ligands **13a** and **13g** bearing *o*-anisyl or ferrocenyl as R¹ substituents at the aminophosphine moiety, also enhanced the enantioselectivity with respect to EPHOS **1** (Table 2, entry 1), for the Pd-catalyzed allylation using benzylamine. In these case, the product (*R*)-**29** was obtained with 33 and 56% e.e., respectively (entries 2 and 6). The epimeric AMPP* ligands (*R*_p)-**13f** and (*S*_p)-**13i** bearing an *o*-biphenyl group either as R¹ or R on the aminophosphine moiety, remarkably, led to the allylated benzylamine **29** with an opposite absolute configuration and with e.e. up to 95% (entries 5 and 8).²³ Results obtained for the catalyzed allylation of dimethyl malonate and benzylamine using palladium complexes derived from AMPP* **20** bearing a P-chirogenic phosphinite moiety, are reported in Table 3.

Table 3. Asymmetric Allylation of Dimethylmalonate and Benzylamine Catalyzed Palladium

Complexes of AMPP* 20



entry	P-chirogenic AMPP* ligand 20		product (<i>S</i>)- 28		product (<i>R</i>)- 29		
	R ¹	R	Yield (%) ^{a,b}	ee (%) ^c	Yield (%) ^{a,b}	ee (%) ^c	
1	EPHOS	Ph	-	42 ^d	90	27	
	1						
2	(<i>R_p</i>)- 20a	<i>o</i> -An	Ph	71	43	87	47
4	(<i>R_p</i>)- 20b	α -Np	"	92	34	85	44
5	(<i>R_p</i>)- 20c	β -Np	"	83	13	87	14
6	(<i>R_p</i>)- 20d	<i>o</i> -Tol	"	87	37	91	27
7	(<i>R_p</i>)- 20f	<i>o</i> -biPh	"	85	50	85	70
8	(<i>R_p</i>)- 20g	Fc	"	64	47	89	56
9	(<i>S_p</i>)- 20i	Ph	<i>o</i> -biPh	85	14	85	34

^a Reactions were carried out in dichloromethane ([**27**] = 0.3 M) with 2 mol% of [Pd(C₃H₅)Cl]₂ and 4 mol% of AMPP* **20**, 2 equiv. of dimethyl malonate or benzylamine as nucleophile, 2 equiv. of *N,O*-bis(trimethylsilyl)acetamide (BSA) and a catalytic amount of KOAc (10 mol%) or 2 equiv. of TBAF as base, respectively. ^b The reaction was performed at room temperature to completion in 7 h. ^c Determined by HPLC on chiral column. ^d Reference 8f.

The allylated products **28** and **29** were obtained with moderate enantioselectivities up to 70% e.e. (Table 3). The P-chirogenic phosphinite substituents of the AMPP* ligands **20** in this catalyzed allylic reaction, did not show significant effect on the stereoselectivity. The products (*S*)-**28** and (*R*)-**29** were obtained with low to moderate enantioselectivities of 13-56% e.e., compared to 27-42% for the EPHOS **1** (Table 3, entries 1-6 and 8). This was after changing the R¹ substituents of AMPP* **20** by *o*-anisyl, α -naphthyl, β -naphthyl, *o*-tolyl or

1 ferrocenyl. However, when $R^1 = \sigma$ -biphenyl, the enantioselectivities obtained for the
2
3
4 products (*S*)-**28** and (*R*)-**29** reached 50 and 70% e.e., respectively (entry 7). When R is an
5
6
7 σ -biphenyl, lower enantioselectivities up to 34% e.e. were obtained using the ligand (*S*_p)-
8
9
10 **20i** compared to epimer (*R*_p)-**20f** (entry 9 vs entry 7). Results in Tables 2 and 3 show that
11
12
13 the enantioselectivities in the palladium catalyzed asymmetric allylic reactions was
14
15
16
17
18 considerably increased with the AMPP* **13** bearing a P-chirogenic aminophosphine moiety,
19
20
21 even if the best asymmetric induction was obtained with the σ -biphenyl-containing AMPP*
22
23
24
25 ligand **20f**.

26
27
28 From a mechanistic standpoint, the P-chirogenic AMPP* ligands **13** and **20** were useful
29
30
31 to improve the understanding of the enantioselectivity (*R* or *S*) in the asymmetric catalyzed
32
33
34 allylations by comparing the structural modifications of the ligands at the aminophosphine
35
36
37 or phosphinite-arms. X-ray structures of the AMPP*.PdCl₂ complexes **30**, **31** and **32**,
38
39
40 prepared by ligand exchange of the dichlorobis(acetonitrile)palladium with the P-chirogenic
41
42
43 AMPP* (*R*_p)-**13f**, (*R*_p)-**13g** and (*R*_p)-**20b**, respectively, are shown Figure 1 and in SI.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


required equatorial positions of the methyl and phenyl substituents of the ephedrine chain (here, *cis*-positioning). A shorter phosphinite-Pd bond was also noted with the Pd1-P2 and Pd1-P1 bond lengths measured between 2.23-2.25Å and 2.26-2.27Å, respectively (Figure 1 and SI). Very similar structures have already been observed in case of rhodium or ruthenium complexes with AMPP derived from ephedrine.^{9b,c,24} Here, the structure of the PdCl₂-complex **30** prepared with the ligand (*R_p*)-**13f** interestingly showed the *o*-biphenyl substituent of the aminophosphine moiety placed perpendicular to the palladium square (*i.e.* P1P2PdCl₂) with a dihedral angle Pd1-P1-C7-C8 of 103.5(4)° (Figure 1a). In addition, the biphenyl group adopted a staggered conformation with a dihedral angle C7-C12-C13-C14 of -46.1(5)°. This could explain the strong influence of the ligand (*R_p*)-**13f** in the palladium sphere of coordination and consequently the high enantioselectivities observed in allylic reactions (Figure 1a; Table 2, entry 5: e.e. up to 82%). By contrast, the *α*-naphthyl substituent in the PdCl₂-complex **32**, located in back area of the Pd-sphere of coordination, might explain the moderate asymmetric induction resulting from ligand (*R_p*)-**20b** (Figure 1b; Table 3, entry 2: e.e. up to 44%).

The origin of the observed enantioselectivity (*i.e.* *R* or *S*) has been addressed by DFT computations, notably for the π -allylpalladium complexes **33-35** derived from the AMPP* ligands (*R_p*)-**13f**, (*S_p*)-**13i** and (*R_p*)-**20f**, respectively (Schemes 5, 6; Table 4 and SI). These

ligands were derived from (+)-ephedrine and bearing a P-chirogenic α -biphenyl-aminophosphine or -phosphinite moiety, led to catalyzed allylations with enantioselectivities up to 91% (*R*) or 95% (*S*) (Table 2, entries 5, 8; Table 3, entry 7).

π -Allylpalladium complexes **33-35** geometry was optimized considering the boat conformation of the seven-membered ring observed in the X-ray structure of PdCl₂-complexes **30-32**. This included changing the two chlorides by the π -allyl ligand (PhCCCPPh). Both preferred M- or W- orientations of the π -allyl moiety coordinated onto the palladium (II), were investigated (see Figures S22-S76, SI). The half-chair conformation in complexes **33-35** were also examined because the biphenyl substituent at the axial position to the Pd-square plane in complexes **34** and **35**, could induce steric hindrance (R^a or $R^c = \alpha$ -biPh, Scheme 5). In total four starting conformations were optimized for the π -allyl complexes **33-35**, named **33-35M-** or **33-35W** (boat or half-chair). A maximal energy differences between all these species of 16.1 KJmol⁻¹ was observed (Scheme 5, Table S61, SI).

Scheme 5. Geometry Optimization of the π -Allylpalladium-AMPP* Complexes 33-35



The optimized structures of complexes **33-35** in the ground state, selected bond lengths, energies, electronic affinities (Fukui function), representation of HOMO/LUMOs and their contributions at C1 and C3 positions of the π -allyl group, are detailed in SI. As the Pd-complexes **34-35** adopted chair or half-chair conformations more or less twisted, for clarity purposes they were denoted as **34-35** (boat or half-chair). A selection of key data from Tables S61, S65 to S76, is reported in Table 4. Among all these optimized structures, the π -allyl Pd-complexes **33W**(boat), **33M**(boat), **34M**(boat), **34W**(boat), **34W**(half-chair), **35M**(boat), **35W**(half-chair) and **35W**(boat) exhibited the lowest calculated total energies with differences not exceeding 3.2 KJmol⁻¹ (Tables 4 and SI). The observed enantioselectivity provided from the nucleophilic attack on either the C1 or C3 of the π -allyl


1 complexed moiety. The Pd-C3 bond, *trans* to the phosphinite moiety in the Pd-square
 2
 3
 4 planar center was most commonly longer than the Pd-C1 bonds and was observed in
 5
 6
 7 similar X-ray structures of the ProNOP ligand **2**.²⁵ However, computations showed that the
 8
 9
 10 Pd-C1 and Pd-C3 bond lengths also depend on the Pd-complex conformation (Table 4).
 11
 12
 13
 14 Even if the electroaffinity values of the C1 and C3 atoms in all π -allyl complexes **33-35** are
 15
 16
 17 of unequal value, the enantioselectivity of the allylation is much better explained by
 18
 19
 20 molecular orbital (MO) than electrostatic interactions between the nucleophile and the π -
 21
 22
 23 allyl moiety (Table 4; see detail Table S61 to S76, SI).²⁶
 24
 25
 26
 27

28
 29
 30 **Table 4. Data Selection of the Optimized Structures of Complexes 33-35 (DFT).**

entr	complex	Relative total energy		Selected bond length		LUMO rel. atomic cont.	
			Δ (KJ mol ⁻¹)	Pd-C3	Pd-C1	C3 (%)	C1 (%)
1	33M (boat)	-65202.8789	2.5	2.36703	2.27063	13.79	10.71
2	33W (boat)	-65202.9047	0	2.33082	2.28902	12.25	11.90
3	34M (boat)	-65202.6722	2.0	2.24787	2.35432	9.06	16.52
4	34W (boat)	-65202.6928	0	2.35003	2.26769	12.73	11.89
5	34W (half-chair)	-65202.6928	0	2.34958	2.26783	15.93	9.81
6	35M (boat)	-65202.7893	3.2	2.27871	2.37415	10.94	13.84
7	35W (boat)	-65202.8227	0	2.27178	2.32581	10.63	13.71
8	35W (half-chair)	-65202.8227	0	2.27193	2.32565	10.64	13.71

1 The most stable Pd-complexes **33M** and **33W**, derived from AMPP* ligand (*R_p*)-**13f**, were
2
3
4 in boat conformation and in equilibrium from each other with an energy difference of 2.5
5
6
7 KJmol⁻¹. This was due to the changing M- or W-shape of the π -allyl group (Scheme 6a;
8
9
10
11 Table 4, entries 1 and 2). In this case, the enantioselectivity was explained by a favored
12
13
14 nucleophilic attack at the C3 position of the complex **33M**(boat), leading to the products
15
16
17 (*S*)-**28** or (*R*)-**29** respectively after reaction with malonate or benzyl amine (Scheme 6a).
18
19
20
21 This selectivity was possible by a longer Pd-C3 bond length and a larger LUMO relative
22
23
24 atomic contribution at the C3 position of the π -allyl group, higher in **33M**(boat) than
25
26
27
28 **33W**(boat). This allows the favored interaction with the nucleophile and consequently the
29
30
31
32 cleavage of the Pd-C3 bond to enantioselectively afford the corresponding allylated
33
34
35
36 product (Table 4, entries 1 and 2).
37
38

39
40 **Scheme 6. Computed Stereochemical Course of Pd-Catalyzed Allylations using AMPP***
41
42 **Ligands (*R_p*)-13f, (*S_p*)-13i or (*R_p*)-20f.**
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



In contrast, the computed structures for the Pd-complex derived from the AMPP* ligand (S_p)-13i indicated three species 34M(boat), 34W(boat) and 34W(half-chair) with lower energy difference by 2 KJ.mol⁻¹ (Table 4, entries 3, 4 and 5). The complex 34 could also be in half-chair conformation (*i.e.* 34W(half-chair)), due to steric hindrance of the biphenyl substituent when it is in axial position with regard to the Pd-square as in boat form (Scheme 5, R^a = biPh, R^{b,c,d} = Ph). The observed enantioselectivities of the products (*R*)-28 and (*S*)-29 were again explained by a favored nucleophilic attack at the C3 position of the complexes 34W(half-chair) or 34W(boat). This was due to their longer Pd-C3 bonds and higher LUMO contributions at their C3 positions *i.e.* 2.35 Å, 15.93% and 12.73%, respectively (Scheme

6b, Table 4, entries 4 and 5). However, the computed Pd-C1 bond length and the LUMO contribution for the complex **34M**(boat) were higher at the C1 than C3 position of the π -allyl group, *i.e.* 2.35 Å and 16.52% *vs* 2.25 Å and 9.06% (Table 4, entry 3). In this case the enantioselectivity was explained by a nucleophilic attack at the C1-position of the π -allyl group. It is noteworthy that all stereochemical course from the three lower stable π -allyl Pd-complexes **34** resulted in the same enantioselectivities, justifying the obtained high enantiomeric excesses up to 95% using the ligand (*S*_p)-**13i** (Scheme 6b).

Finally, the more stable optimized complexes **35** derived from AMPP* ligand (*R*_p)-**20f** were either in boat or in half-chair conformation and with a π -allyl group in both M- or W-shape (Scheme 6c; Table 4, entries 6, 7 and 8). All these species were in equilibrium from each other with an energy difference of 3.2 KJ.mol⁻¹. The modest enantioselectivity was explained by a nucleophilic attack at the C1 position of the complexes **35W**(boat) or **35W**(half-chair), but also in a lesser extent of **35M** (boat) which led to reverse enantiomers (*R*)-**28** or (*S*)-**29**. This was due in all case to their longer Pd-C1 than Pd-C3 bonds and their higher LUMO contributions at the C1 rather than C3 position, *i.e.* 2.37 Å and 13.84%, 2.33 Å and 13.71% *vs* 2.27 Å and 10.63%, respectively (Scheme 6b, Table 4, entries 6, 7 and 8).

3. CONCLUSION

We have developed an important series of chiral aminophosphine-phosphinite ligands bearing a chirality at the phosphorus atom of the aminophosphine or phosphinite moiety (AMPP*). Until now the design of AMPP* with a P-chirogenic phosphinite center has been poorly investigated. We synthesized this series with the ephedrine methodology used in stereoselective synthesis of P-chirogenic phosphines. The synthesis of AMPP* ligands with P-chirogenic aminophosphine moieties is based on the stereospecific ring opening of an oxazaphospholidine-borane by reaction with organolithium reagents, trapping the aminophosphine-borane intermediates with a chlorophosphine and borane decomplexation. A broader design of AMPP* ligands notably on phosphinite center was achieved thanks to an unprecedented stereospecific N→O phosphinyl migration process recently developed in our group. When the aminophosphine-boranes were heated at 50°C in the presence of DABCO, P-chirogenic phosphinites were obtained by N→O phosphinyl migration. Their reaction with chlorophosphines led then to the corresponding free AMPP* with P-chirogenic phosphinite moiety. Synthesis efficiency was demonstrated by the stereoselective synthesis of the four epimers of the *o*-biphenyl containing AMPP* ligands, with (*S*)- or (*R*)- absolute configuration at the P-centers. Twenty nine AMPP* including eight with a P-chirogenic phosphinite moiety were investigated in palladium-catalyzed

1 asymmetric allylic reactions. The enantioselectivities varied from 91% (*R*) to 95% e.e. (*S*),
2
3
4 according to the spatial position of the P-substituents in the palladium sphere of
5
6
7 coordination. The best asymmetric inductions were obtained with AMPP* bearing P-
8
9
10 chirogenic aminophosphine moieties. The (*S*)- or (*R*)-enantioselectivity depends on the
11
12
13 absolute configuration at the phosphorus atom. X-ray crystallographic data for relevant Pd-
14
15
16 AMPP* complexes and computer modeling explained enantioselectivities origin, based on
17
18
19 MO interactions of the most stable conformers with nucleophiles. The selectivity provided
20
21
22 from the nucleophilic attack at the C3 or C1 position of the complexed π -allyl group. It was
23
24
25 favored by the interaction of the nucleophile with the LUMO having the larger contribution
26
27
28 in one of those positions, and also by the cleavage of the corresponding longer Pd-C3 or
29
30
31 Pd-C1 bond.
32
33
34
35
36
37
38

39 To conclude, this methodology to prepare P-chirogenic modified EPHOS ligands derived
40
41
42 from ephedrine, opens up further possibilities for optimizing and predict enantioselectivities
43
44
45 in asymmetric catalyzed processes by designing AMPP* derived from aminoalcohols.
46
47
48
49
50
51
52

53 4. EXPERIMENTAL SECTION

54
55
56 **4.1. General Information.** All reactions were carried out using standard Schlenk
57
58
59 techniques under an inert atmosphere, unless stated otherwise. Dichloromethane, toluene,
60

1 pentane, THF and diethylether were dried using a MBRAUN SPS 800. Chromatographic
2
3
4 grade hexane and isopropanol for HPLC were used without further purification.
5
6
7 Commercially available methyllithium, *s*-butyllithium, *t*-butyllithium,
8
9
10 chlorodiphenylphosphine, phosphorus trichloride, N-methylmorpholine, 1-
11
12
13 bromonaphtalene, 2-bromonaphtalene, 2-bromobiphenyl and bromocyclohexane were
14
15
16 used without purification, whereas 2-bromoanisole was distilled before use. EPHOS 1
17
18
19 and AMPP* **13a-c**, **13f-h**, **13j-l**, **13u** and their corresponding diborane complexes **12** were
20
21
22 synthesized according to literature procedures.^{9a,b,10a} The 2-benzyloxy-^{27a} and 2-
23
24
25 isopropoxybromobenzene^{27b} were prepared from 2-bromophenol according to reported
26
27
28 procedures. The 4-bromo-2,6-bis(*t*-butyl)anisole was synthesized from 4-bromo-2,6-bis(*t*-
29
30
31 butyl)phenol, according to a modified procedure using K₂CO₃ as base.^{27c} The bromo-2,6-
32
33
34 dimethoxybiphenyl has been prepared and generously provided by Dr F. Leroux (LIMA-
35
36
37 Strasbourg).²⁸ Thin layer chromatography was performed on silica chromagel (60 μm F₂₅₄)
38
39
40 and exposed by UV, potassium permanganate or iodine treatment. Flash chromatography
41
42
43 was carried out with the indicated solvents using silica gel 60 (60AAC, 35-70 μm). HPLC
44
45
46 analyses were performed on a chromatograph equipped with a UV detector at λ = 210 and
47
48
49 254 nm. The ¹H, ¹³C{¹H} and ³¹P{¹H} NMR spectra were recorded on 600, 500, 400 or 300
50
51
52 MHz spectrometers at ambient temperature, using tetramethylsilane (TMS) as internal
53
54
55
56
57
58
59
60

reference for ^1H and ^{13}C spectra, and phosphoric acid (85%) as external reference for ^{31}P NMR. Data were reported as s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br.s = broad signal, coupling constant(s) in Hertz. Infrared spectra were recorded on FT-IR instrument and the data are given in cm^{-1} . Melting points were measured on a Kofler melting points apparatus. Optical rotation values were determined at 20 °C on a polarimeter at 589 nm (sodium lamp). The mass spectra and accurate mass measurements (HRMS) were performed under (ESI) conditions with a micro Q-TOF detector or Orbitrap detector, or in the MALDI/TOF reflectron mode using dithranol as a matrix. Elemental analyses were performed with a precision superior to 0.3% on a CHNS-O instrument apparatus.

Crystal Structure Determination. All experimental data procedure and refinement are detailed in the part B of the Supplementary Information (SI) for each compound. Data CCDC-1982667, 1982668, 1982669, 1982665, 1982666, 1982663, 1982664, 1982661, 1982662, 1982659, 1982660, 1982656, 1982657, 1982658, 1982652, 1982653, 1982654, 1982650 and 1982651 for compounds (R_p)-**11e**, (R_p)-**11h**, (M,S_p)-**11v**, R_p -**12f**, (R_p)-**12g**, (S_p)-**12i**, (S_p)-**15e**, (S_p)-**21a**, (S_p)-**21b**, (R_p)-**21c**, (R_p)-**21d**, (S_p)-**21d**, (R_p)-**21e**, (R_p)-**21f**, (R_p)-**21g**, (S_p)-**21h**, **30**, **31** and **32**, respectively contain the supplementary crystallographic data

for this paper. These data can be obtained free of charge from The Cambridge
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif

Computational Details All density functional theory (DFT) calculations were performed with Gaussian 16 and were detailed in the Supplementary Information (part C, SI). The DFT ground state calculations were carried out using the B3LYP/genecp method. A 6-31g (d, p) basis set was used for C, H, N and O atoms. VDZ (valence double ζ) with SBKJC effective core potentials was used for P and Pd atoms.

4.2. Synthesis of the oxazaphospholidine-2-borane complexes 10.

4.2.1. (2*S*,4*R*,5*S*)-3,4-Dimethyl-2,5-diphenyl-1,3,2-oxazaphospholidine-2-borane (-)- and (+)-10a. These starting compounds were prepared from bis(dimethylamino)phenylphosphine and (+)- and (-)-ephedrine **9**, respectively, according to a methodology already described.^{9,15}

4.2.2. (2*S*,4*R*,5*S*)-3,4-Dimethyl-2-biphenyl-5-phenyl-1,3,2-oxazaphospholidine-2-borane (-)-10b. This compound was prepared from 2-chloro-1,3,2-oxazaphospholidine according to a modified procedure using *o*-biphenyllithium as reagent.^{14,15} To a solution of 2-chloro-1,3,2-oxazaphospholidine (1 mmol) previously prepared by reaction of PCl₃ with the (+)-ephedrine **9** and *N*-methylmorpholine, was added at -78 °C a solution of *o*-biphenyllithium in diethyl ether (0.7 mmol). After stirring overnight, borane-dimethylsulfide (1.1 mmol) was added and the mixture was stirred under argon for 6 h. After hydrolysis, the organic phase

1 was successively extracted with ethyl acetate, dried over MgSO₄ and filtered. The solvent
2
3
4 was removed under vacuum and the residue was purified by chromatography on silica gel
5
6
7 using a mixture of petroleum ether/dichloromethane (1:1) as eluent. The
8
9
10 oxazaphospholidine-borane complex (-)-**10b** was recrystallized from a mixture of
11
12
13 methanol/dichloromethane. 0.16 g, 43% yield; White crystals; Mp = 155 °C; R_f = 0.53
14
15
16 (petroleum ether/dichloromethane 1/1); [α]_D²⁰ = -12.8 (c 0.3, CHCl₃). ¹H NMR (300 MHz,
17
18 CD₂Cl₂): δ -0.18-1.24 (m, 3H), 0.50 (d, *J* = 6.5 Hz, 3H), 2.32 (d, *J* = 10.2 Hz, 3H), 3.21-3.33
19
20
21 (m, 1H), 4.56 (dd, *J* = 6.0, 2.3 Hz, 1H), 7.02-7.06 (m, 2H), 7.14-7.22 (m, 4H), 7.26 (br.s,
22
23
24 5H), 7.30-7.43 (m, 2H), 7.77 (ddd, *J* = 11.8, 7.4, 1.2 Hz, 1H). ³¹P{¹H} NMR (121.5 MHz,
25
26
27 CD₂Cl₂): δ 132.5 (br.s). Anal. calcd for C₂₂H₂₅BNOP: C 73.15, H 6.98, N 3.88; found
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
C 73.02, H 7.03, N 3.98.

4.3. Synthesis of aminophosphine-boranes 11.

4.3.1. *Preparation of aryllithium reagents by metal/halide exchange.* To a solution of
bromoaryl derivatives (2 M) in THF was added 1 equivalent of *s*-butyllithium at 0 °C or 2
equivalents of *t*-butyllithium at -78 °C. After the formation of a white precipitate, the mixture
was stirred at 0 °C for 1 h (or at -78 °C in the second case). The organolithium reagent was
dissolved with a minimum of dry THF before use.

1 4.3.2. *Preparation of ferrocenyllithium reagent by ferrocene deprotonation.* A 50 mL
2
3
4 three-necked flask equipped with a magnetic stirrer under an argon atmosphere was
5
6
7 charged with ferrocene (0.74 g, 4 mmol) and THF (10 mL). At 0 °C, *t*-BuLi (2.75 mL, 1.6 M
8
9
10 in hexane, 4.4 mmol) was added dropwise, and the reaction mixture was stirred at 0 °C for
11
12
13
14 1 h, before use.

15
16
17
18 4.3.3. *Synthesis of aminophosphine-boranes 11: General procedure.* In a 50 mL three-
19
20
21 necked flask, equipped with a magnetic stirrer and an argon inlet, 5 mmol of the
22
23
24 oxazaphospholidine borane complex **10** were dissolved in 5 mL of anhydrous THF. The
25
26
27 mixture was cooled at – 78 °C and 2 equiv. (10 mmol) of the organolithium reagent were
28
29
30 slowly added. The resulting mixture was stirred and warmed to RT until the starting
31
32
33 material was completely consumed, and hydrolyzed at 0 °C with 2 mL of water. The THF
34
35
36 was removed under reduced pressure and the aqueous layer was extracted several times
37
38
39 with dichloromethane. The combined organic phases were dried over MgSO₄ and the
40
41
42 solvent was removed. The residue was purified by chromatography on a column of silica
43
44
45 gel, using a mixture of toluene/AcOEt as eluent, to afford aminophosphine-boranes **11**. The
46
47
48 aminophosphine-boranes **11** were typically recrystallized using a mixture of
49
50
51 hexane/isopropanol (7:3).
52
53
54
55
56
57
58
59
60

4.3.4. The *o*-anisyl-,^{11b} α -naphthyl-,^{11b,29} β -naphthyl-,^{11b,29b} *o*-tolyl-,^{30,31} *p*-tolyl-,³¹ *o*-biphenyl-,^{11b,29,30} ferrocenyl-,^{11b,14,30} *t*-butyl-,^{11b,32} methyl-,^{10,11b} cyclohexyl-,^{11b} *o*-[(2-methoxyethoxy)methoxy]phenyl-,^{9b} *o*-isopropoxyphenyl-,³¹ 3,5-xylyl-,¹⁵ 3,5-di-*t*-butylphenyl-,³³ 2-(2',6'-dimethoxy)biphenyl-,³⁴ calix[4]arenyl-,^{9c} aminophosphines **11a-h**, **11j-m**, **11o**, **11p**, **11u**, respectively, were prepared from the appropriate oxazaphospholidine-borane complex (+)- or (-)-**10a** or (-)-**10b**, according to the described procedure. These compounds exhibited satisfactory analytical and spectrochemical data in agreement with the literature.

4.3.5. (*R_p*)-(-)-*N*-[(1*R*,2*S*)-2-Hydroxy-1-methyl-2-phenylethyl], *N*-methylamino(phenyl-*p*-tolyl) phosphine-borane **11e**.³¹ This compound was synthesized by reaction of oxazaphospholidine-borane complex (-)-**10a** with *p*-tolyllithium reagent. Colorless crystals (1.64 g, 87% yield). X-ray quality crystals were grown by slow evaporation of hexane. The structure and the data were reported in the SI; $R_f = 0.25$ (toluene/ethyl acetate 9:1); $[\alpha]_D^{20} = -44.3$ (c 0.5, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ 0.20-2.00 (m, 3H), 1.26 (d, $J = 6.7$ Hz, 3H), 1.89 (br.s, 1H), 2.41 (s, 3H), 2.49 (d, $J = 7.8$ Hz, 3H), 4.25-4.39 (m, 1H), 4.83 (d, $J = 6.6$ Hz, 1H), 7.14-7.20 (m, 2H), 7.25-7.44 (m, 8H), 7.47-7.53 (m, 4H). ¹³C{¹H} NMR (75.5 MHz, CDCl₃): δ 13.5 (d, $J = 1.2$ Hz), 21.5, 30.4 (d, $J = 3.7$ Hz), 58.1 (d, $J = 10.1$ Hz), 78.7 (d, $J = 6.1$ Hz), 126.8, 127.6 (d, $J = 61.7$ Hz), 127.9, 128.3 (d, $J = 10.7$ Hz), 128.5, 129.2

(d, $J = 10.2$ Hz), 130.6 (d, $J = 2.3$ Hz), 130.9 (d, $J = 68.3$ Hz), 132.0 (d, $J = 10.5$ Hz), 132.5 (d, $J = 10.6$ Hz), 141.5 (d, $J = 2.3$ Hz), 142.5. $^{31}\text{P}\{^1\text{H}\}$ NMR (121.5 MHz, CDCl_3): δ +69.8-70.2 (m). HRMS (ESI/Q-TOF) calcd for $\text{C}_{23}\text{H}_{29}\text{BNOPNa}$ $[\text{M}+\text{Na}]^+$: 400.19720; found: 400.19738. Anal. calcd for $\text{C}_{23}\text{H}_{29}\text{BNOP}$: C 73.22, H 7.75, N 3.71; found C 73.10, H 7.73, N 3.62.

4.3.6. *(S_p)-(+)-N-[(1R,2S)-2-Hydroxy-1-methyl-2-phenylethyl], N-methylamino(o-biphenyl) phenylphosphine-borane 11i*. This compound was synthesized by reaction of oxazaphospholidine-borane complex (-)-**10b** with phenyllithium reagent. White solid (1.91 g, 87% yield); Mp = 56-58 °C; $R_f = 0.45$ (CH_2Cl_2); $[\alpha]_{\text{D}}^{20} = +9.9$ (c 0.6, CHCl_3). ^1H NMR (300 MHz, CD_2Cl_2): δ 0.52-1.82 (m, 3H), 0.85 (d, $J = 6.9$ Hz, 3H), 2.43 (d, $J = 8.0$ Hz, 3H), 4.17-4.22 (m, 1H), 4.52-4.53 (m, 1H), 7.02-7.07 (m, 1H), 7.13-7.17 (m, 3H), 7.23-7.30 (m, 4H), 7.33-7.45 (m, 8H), 7.48-7.54 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125.8 MHz, CD_2Cl_2): δ 11.4, 30.8 (d, $J = 5.0$ Hz), 57.8 (d, $J = 10.0$ Hz), 78.1 (d, $J = 7.7$ Hz), 126.4, 126.9, 127.0, 127.5, 127.7 (d, $J = 9.8$ Hz), 128.3, 128.4 (d, $J = 65.6$ Hz), 130.1, 130.3 (d, $J = 2.1$ Hz), 130.3 (d, $J = 2.1$ Hz), 130.6 (d, $J = 2.2$ Hz), 131.3 (d, $J = 52.9$ Hz), 132.3 (d, $J = 9.8$ Hz), 132.6 (d, $J = 8.8$ Hz), 133.7 (d, $J = 9.8$ Hz), 141.3 (d, $J = 2.7$ Hz), 143.0, 146.7 (d, $J = 9.6$ Hz). $^{31}\text{P}\{^1\text{H}\}$ NMR (121.5 MHz, CD_2Cl_2): δ +70.7 (br.s). FTIR (neat): ν_{max} 3448, 2961, 2897, 2388, 1643, 1604,

1535, 1493, 1446, 1157, 1064, 998, 951, 912, 886, 751, 697, 636 cm^{-1} . HRMS (ESI/Q-TOF) calcd for $\text{C}_{28}\text{H}_{31}\text{BNOPNa}$ $[\text{M}+\text{Na}]^+$: 462.2129; found: 462.2120.

4.3.7. *(R_p)-N-[(1R,2S)-2-Hydroxy-1-methyl-2-phenylethyl], N-(methylamino)phenyl(2-pyridyl) phosphine-borane 11r*. This compound was synthesized by reaction of oxazaphospholidine-borane complex (-)-**10a** with 2-pyridinyl lithium reagent. ^1H NMR (300 MHz, CDCl_3): δ 0.40-1.70 (m, 3H), 1.18 (d, $J = 6.8$ Hz, 3H), 2.64 (d, $J = 8.5$ Hz, 3H), 3.04-3.06 (m, 1H), 4.10-4.20 (m, 1H), 4.82 (dd, $J = 5.2, 5.0$ Hz, 1H), 7.16-7.17 (m, 2H), 7.28-7.48 (m, 9H), 7.76-7.85 (m, 1H), 7.95-8.03 (m, 1H), 8.79 (d, $J = 3.3$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75.5 MHz, CDCl_3): δ 13.7 (d, $J = 1.6$ Hz), 31.1, 58.4 (d, $J = 6.7$ Hz), 78.2 (d, $J = 5.9$ Hz), 124.9 (d, $J = 2.4$ Hz), 126.9, 128.2 (d, $J = 42.0$ Hz), 128.5, 128.6, 129.2 (d, $J = 26.0$ Hz), 130.3 (d, $J = 72.0$ Hz), 131.0 (d, $J = 2.2$ Hz), 132.3 (d, $J = 7.2$ Hz), 136.3 (d, $J = 9.4$ Hz), 142.4, 149.9 (d, $J = 12.6$ Hz), 156.5 (d, $J = 73.2$ Hz). $^{31}\text{P}\{^1\text{H}\}$ NMR (121.5 MHz, CDCl_3): δ +69.6 (br.s). Anal. calcd for $\text{C}_{21}\text{H}_{26}\text{BN}_2\text{OP}$: C 69.25, H 7.20, N 7.69; found C 69.14, H 7.25, N 7.95.

4.3.8. *(M, S_p)-(+)-N-[(1S,2R)-2-(Hydroxy-1-methyl-2-phenylethyl)], N-methylamino-2-(1,1'-binaphthyl)phenylphosphine-borane 11v*. To a solution of (2*R*,4*S*,5*R*)-3,4-dimethyl-2,5-diphenyl-1,3,2-oxazaphospholidine-2-borane (+)-**10a** (1.0 g, 3.5 mmol) in THF (6 mL) was added at -78 °C 1,1'-binaphth-2-yl lithium. It was previously prepared by slow addition at -78

1 °C of *t*-butyllithium (1.9 M in hexane, 7.4 mL, 14 mmol) to a solution of (±)-2-bromo-1,1'-
2
3
4 binaphthyl **17** (2.3 g, 7 mmol) in Et₂O (3.5 mL) and stirring at this temperature during one
5
6
7 hour. The reaction mixture was stirred overnight until it reached room temperature, and 20
8
9
10 mL of water was added. The aqueous phase was extracted with CH₂Cl₂ (3 x 20 mL). The
11
12
13 organic extracts were dried over anhydrous MgSO₄ and the solvent was evaporated. The
14
15
16 crude product was purified by chromatography on silica gel using CH₂Cl₂ as eluent to give
17
18
19 the aminophosphine-borane **11v** as a mixture of diastereoisomers in 85:15 ratio.
20
21
22 Recrystallization in ethyl acetate afforded the titled compound as only one diastereoisomer.
23
24
25 The X-ray structure and the data were reported in the SI. White solid (0.72 g, 38% yield). *R*_f
26
27
28 = 0.41 (CH₂Cl₂); [α]_D²⁰ = +18.0 (c 0.3, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 0.40-1.38 (m,
29
30
31 3H), 0.46 (d, *J* = 7.1 Hz, 3H), 2.56 (d, *J* = 7.7 Hz, 3H), 3.71-3.74 (m, 1H), 4.86-4.87 (m,
32
33
34 1H), 7.02 (d, *J* = 8.4 Hz, 1H), 7.12-7.27 (m, 10H), 7.35-7.43 (m, 4H), 7.52 (t, *J* = 7.5 Hz,
35
36
37 1H), 7.57-7.62 (m, 3H), 7.82-7.85 (m, 2H), 7.91-7.92 (m, 2H). ¹³C{¹H} NMR (125.8 MHz,
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
60 CDCl₃): δ 9.7 (d, *J* = 5.5 Hz), 32.6 (d, *J* = 3.5 Hz), 57.9 (d, *J* = 9.4 Hz), 78.9, 125.1, 125.5,
125.6, 125.7, 126.7, 126.9, 127.1, 127.5 (d, *J* = 9.8 Hz), 127.6, 127.8, 127.9, 128.1, 128.2,
128.5, 129.3 (d, *J* = 10.7 Hz), 129.8, 130.3 (d, *J* = 2.0 Hz), 131.9 (d, *J* = 9.8 Hz), 133.2,
133.4, 133.7, 134.0 (d, *J* = 9.7 Hz), 134.1, 134.2 (d, *J* = 7.2 Hz), 134.8 (d, *J* = 4.0 Hz),
142.6, 144.2 (d, *J* = 9.9 Hz). ³¹P{¹H} NMR (202.5 MHz, CDCl₃): δ +71.7 (br.s). FTIR

(neat): ν_{\max} 3520, 3078, 2830, 2380, 2365, 1450, 1437, 1385, 1367, 1163, 1106, 1062, 1022, 998, 883, 822 cm^{-1} . HRMS (ESI/Q-TOF) calcd for $\text{C}_{36}\text{H}_{35}\text{BNOPNa}$ $[\text{M}+\text{Na}]^+$: 562.2448; found: 562.2446.

4.4. Synthesis of the AMPP*-diboranes 12a-w with P-chirogenic aminophosphine moieties.

4.4.1. Typical procedures: AMPP*-diborane complexes **12** were obtained either according to a one-pot procedure from the oxazaphospholidine-2-borane **10** (Method A), or by deprotonation of the isolated aminophosphine-borane **11** (Method B).

4.4.1.1. From oxazaphospholidine borane 10 (Method A). To a solution of 3,4-dimethyl-5-phenyl-1,3,2-oxazaphospholidine-2-borane **10** (3.5 mmol) in THF (6 mL) was slowly added at $-78\text{ }^{\circ}\text{C}$ the organolithium reagent (7 mmol). The temperature reaction was slowly warmed to $0\text{ }^{\circ}\text{C}$ and the solution was stirred until the starting material was completely consumed. Chlorophosphine $\text{R}'_2\text{PCI}$ (7 mmol; $\text{R}' = \text{Ph}, \alpha\text{-Np}$ or $3,5\text{-Xyl}$) was added and the mixture was stirred for 2 h. Borane-dimethylsulfide complex (2.7 mL, 28 mmol) was slowly added at $0\text{ }^{\circ}\text{C}$ and the reaction mixture was stirred overnight until the solution reached room temperature. Water (20 mL) was added and the aqueous phase was extracted with CH_2Cl_2 (3 x 20 mL). The organic extracts were dried over anhydrous MgSO_4 and the

1 solvent was evaporated. The crude product was purified by chromatography on silica gel
2
3
4 and, in some cases, by recrystallization to afford the desired AMPP*-diboranes **12**.
5
6

7 *4.4.1.2. From aminophosphine-borane 11 (Method B).* To a solution of aminophosphine-
8
9 borane **11** (0.5 mmol) in THF (1 mL) was slowly added at -78 °C *n*-BuLi (0.6 mmol). After
10
11 stirring during one hour at -78 °C, chlorophosphine R₂PCl (1.1 mmol) was added and the
12
13 resulting mixture was stirred until the solution reached room temperature (~ 5 h). Borane-
14
15 dimethylsulfide complex (4 mmol) was added at 0 °C and the solution was stirred overnight
16
17
18 before hydrolysis with water (10 mL). The work-up is similar as described above.
19
20
21
22
23
24
25
26
27

28 *4.4.2. The EPHOS⁸ and the AMPP*-diborane complexes 12a-c,^{9a,b} 12f-h,^{9b} 12j,^{9a,b,10}*
29
30 **12k, 12l,^{9b} 12u^{9c} and 15e,^{9a}** were synthesized as described in literature.
31
32
33
34

35 *4.4.3. (S_p)-(-)-N-[(1R,2S)-2-(Diphenylphosphinito-borane)-1-methyl-2-phenylethyl], N-*
36
37 *methyl amino(o-biphenyl)phenylphosphine-borane 12i.* The synthesis of **12i** was achieved
38
39 using the method A (as described above) by reaction of the complex (-)-**10b** (1.26 g, 3.5
40
41 mmol) in THF (6 mL) at -78 °C with phenyllithium (1.8 M in dibutylether, 3.9 mL, 7 mmol).
42
43
44
45
46
47
48
49 The ring opening product [**11i**] was then trapped by Ph₂PCl. The purification was achieved
50
51
52 by chromatography on silica gel using petroleum ether/CH₂Cl₂ 1:1 as eluent and
53
54
55
56 recrystallization in hexane/dichloromethane to give the AMPP*-diborane **12i** as a white
57
58
59 solid (1.16 g, 52% yield). X-ray quality crystals were grown by slow evaporation of a
60

1 mixture of CH₂Cl₂ and hexane. The structure and the data were reported in the SI. R_f =
2
3
4 0.62 (petroleum ether/CH₂Cl₂ 1:1); Mp = 206-208 °C; $[\alpha]_D^{20}$ = -52.2 (c 0.4, CHCl₃). ¹H NMR
5
6
7 (500 MHz, CD₂Cl₂): δ 0.56-1.73 (m, 6H), 1.03 (d, J = 6.6 Hz, 3H), 2.19 (d, J = 7.7 Hz, 3H),
8
9
10 4.69-4.77 (m, 1H), 5.42 (t, J = 9.1 Hz, 1H), 6.27 (ddd, J = 12.2, 2.1, 1.2 Hz, 1H), 6.89-6.96
11
12
13 (m, 4H), 7.07-7.24 (m, 8H), 7.32-7.42 (m, 9H), 7.48-7.56 (m, 5H), 7.73-7.78 (m, 2H).
14
15
16
17
18 ¹³C{¹H} NMR (125.8 MHz, CD₂Cl₂): δ 15.2, 29.2 (d, J = 4.9 Hz), 57.2 (dd, J = 10.0, 8.9 Hz),
19
20
21 83.5 (dd, J = 10.4, 2.7 Hz), 126.8, 126.9, 127.1 (d, J = 9.5 Hz), 127.4 (d, J = 10.1 Hz),
22
23
24 127.7, 127.9, 128.0, 128.3, 128.5 (d, J = 10.7 Hz), 128.7, 129.0, 129.0 (d, J = 54.1 Hz),
25
26
27 130.0, 130.1 (d, J = 2.4 Hz), 130.5 (d, J = 1.8 Hz), 131.0 (d, J = 10.7 Hz), 131.4 (d, J = 1.8
28
29 Hz), 131.5, 131.6, 131.7 (d, J = 1.8 Hz), 132.0 (d, J = 59.4 Hz), 132.3 (d, J = 8.9 Hz), 132.5
30
31 (d, J = 10.1 Hz), 132.8, 132.9 (d, J = 7.7 Hz), 138.4, 140.5 (d, J = 2.6 Hz), 146.4 (d, J =
32
33 11.0 Hz). ³¹P{¹H} NMR (202.5 MHz, CD₂Cl₂): δ +69.7-70.0 (m), +106.5-106.9 (m). FTIR
34
35
36 (neat): ν_{\max} 3054, 2933, 2393, 2353, 1457, 1437, 1220, 1159, 1135, 1115, 1066, 1011,
37
38 974, 892, 864, 760, 738, 715 cm⁻¹. HRMS (ESI/Q-TOF) calcd for C₄₀H₄₃B₂P₂NONa
39
40 [M+Na]⁺: 660.2911; found: 660.2896. Anal. calcd for C₄₀H₄₃B₂P₂NO: C 75.38, H 6.80,
41
42 N 2.20; found: C 75.03, H 6.92, N 2.29.
43
44
45
46
47
48
49
50
51
52
53
54
55

56 4.4.4. (*R_p*)-(-)-*N*-[(1*R*,2*S*)-2-(Diphenylphosphinito-borane)-1-methyl-2-phenylethyl], *N*-
57
58
59
60 methyl amino(2-isopropoxyphenyl)phenylphosphine-borane **12m**. The synthesis of **12m**

was achieved using the method A (as described above), by reaction of the complex (-)-**10a** (1.0 g, 3.5 mmol) with the 2-*i*-propyloxyphenyllithium previously prepared from 1-bromo-2-*i*-propyloxybenzene (1.5 g, 7 mmol) in THF (3.5 mL) and *s*-BuLi (1.4 M in cyclohexane, 5.0 mL, 7 mmol). The ring opening product [**11m**] was then trapped by Ph₂PCl. The purification was achieved by column chromatography on silica gel using petroleum ether/toluene (1:1) as eluent. White crystals (1.06 g, 54% yield). $R_f = 0.10$ (petroleum ether/toluene 1:1); Mp = 172-174 °C; $[\alpha]_D^{20} = -50.7$ (c 1.5, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 0.33-1.61 (m, 6H), 0.68 (d, $J = 6.2$ Hz, 3H), 0.78 (d, $J = 6.2$ Hz, 3H), 1.25 (d, $J = 6.2$ Hz, 3H), 2.37 (d, $J = 7.8$ Hz, 3H), 4.27 (hept, $J = 6.2$ Hz, 1H), 4.52-4.59 (m, 1H), 5.32 (t, $J = 8.8$ Hz, 1H), 6.50 (2d, $J = 7.7$ Hz, 2H), 6.69 (dd, $J = 4.2, 2.3$ Hz, 1H), 6.90-6.95 (m, 3H), 7.00-7.44 (m, 15H), 7.61-7.67 (m, 2H), 7.80 (ddd, $J = 1.5, 7.6, 13.8$ Hz, 1H). ¹³C{¹H} NMR (100.6 MHz, CDCl₃): δ 16.1, 20.6, 21.1, 29.8 (d, $J = 5.1$ Hz), 57.5 (dd, $J = 8.3, 11.3$ Hz), 69.0, 83.5 (dd, $J = 2.9, 11.5$ Hz), 111.7 (d, $J = 4.1$ Hz), 118.1 (d, $J = 54.2$ Hz), 120.1 (d, $J = 10.8$ Hz), 127.6 (d, $J = 11.2$ Hz), 127.8 (d, $J = 10.6$ Hz), 128.1, 128.3, 128.5 (d, $J = 10.6$ Hz), 128.8, 129.3 (d, $J = 2.1$ Hz), 130.2 (d, $J = 11.2$ Hz), 131.1 (d, $J = 11.3$ Hz), 131.3 (d, $J = 2.0$ Hz), 131.6 (d, $J = 11.7$ Hz), 131.7 (d, $J = 2.0$ Hz), 132.2 (d, $J = 7.8$ Hz), 132.3 (d, $J = 76.4$ Hz), 132.9, 133.2 (d, $J = 1.5$ Hz), 136.1 (d, $J = 14.1$ Hz), 138.1, 158.6. ³¹P{¹H} NMR (161.9 MHz, CDCl₃): δ +68.3 (br.s), +106.4 (br.s). FTIR (neat): ν_{\max} 3080-3010, 2978-2819, 2391, 2378, 2346,

1587, 1572, 1471, 1456, 1437, 1383, 1372, 1275, 1244, 1222, 1164, 1132, 1113, 1061,
1013, 983, 952, 890, 865, 768, 752, 735, 714, 694 cm⁻¹. HRMS (ESI/Q-TOF) calcd for
C₃₇H₄₄B₂NO₂P₂ [M-H]⁺: 618.3033; found 618.3043. Anal. calcd for C₃₇H₄₅B₂NO₂P₂:
C 71.75, H 7.32, N 2.26; found C 72.02, H 7.56, N 2.32.

4.4.5. (*R_p*)-(-)-*N*-[(1*R*,2*S*)-2-(Diphenylphosphinito-borane)-1-methyl-2-phenylethyl], *N*-methyl amino(2-benzyloxyphenyl)phenylphosphine-borane **12n**. The synthesis of **12n** was achieved using the method A (as described above), by reaction of the complex (-)-**10a** (1.0 g, 3.5 mmol) with the 2-benzyloxyphenyllithium reagent, previously prepared using 2-benzyloxybromobenzene (1.8 g, 7 mmol) in THF (3.5 mL) and *s*-BuLi (1.4 M in cyclohexane, 5.0 mL, 7 mmol). The ring opening product [**11n**] was then trapped by Ph₂PCI. The purification was achieved by column chromatography on silica gel using petroleum ether/toluene (1:1) as eluent. White crystals (1.05 g, 45% yield). *R_f* = 0.10 (petroleum ether/toluene 1:1); Mp = 140-142 °C; [α]_D²⁰ = -36.5 (c 1.9, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ 0.20-1.60 (m, 6H), 1.22 (d, *J* = 6.6 Hz, 3H), 2.27 (d, *J* = 7.8 Hz, 3H), 4.45-4.60 (m, 1H), 4.69 (s, 2H), 5.27 (t, *J* = 9.2 Hz, 1H), 6.53 (dd, *J* = 7.4, 11.7 Hz, 2H), 6.63 (d, *J* = 6.9 Hz, 2H), 6.85-7.41 (m, 22H), 7.60-7.80 (m, 3H). ¹³C{¹H} NMR (75.5 MHz, CDCl₃): δ 15.9, 29.8 (d, *J* = 4.5 Hz), 57.5 (br.s), 70.1, 83.4 (d, *J* = 9.8 Hz), 112.3 (d, *J* = 4.5 Hz), 118.2, 118.9, 121.2 (d, *J* = 11.3 Hz), 126.8, 127.6, 127.8, 128.0 (d, *J* = 9.1 Hz), 128.2,

128.3, 128.5 (d, $J = 10.6$ Hz), 128.8, 129.6 (d, $J = 2.0$ Hz), 130.4 (d, $J = 10.6$ Hz), 131.0, 131.2, 131.3 (d, $J = 2.0$ Hz), 131.5, 131.7, 132.0, 132.2 (d, $J = 8.3$ Hz), 132.9, 133.5, 135.8, 136.0 (d, $J = 13.6$ Hz), 138.0, 159.9. $^{31}\text{P}\{^1\text{H}\}$ NMR (121.5 MHz, CDCl_3): δ +68.7 (br.s), +106.7 (br.s). FTIR (neat): ν_{max} 3083-3040, 2976-2854, 2344, 2299, 1570, 1546, 1465, 1437, 1363, 1250, 1223, 1130, 1115, 1066, 1043, 999, 973, 922, 914, 860, 831, 740, 714, 694 cm^{-1} . HRMS (ESI/Q-TOF) calcd for $\text{C}_{41}\text{H}_{46}\text{B}_2\text{P}_2\text{NO}_2$ $[\text{M}+\text{H}]^+$: 668.3190; found: 668.3195.

4.4.6. *(R_p)-(-)-N-[(1R,2S)-2-(Diphenylphosphinito-borane)-1-methyl-2-phenylethyl], N-methyl amino(3,5-dimethylphenyl)phenylphosphine-borane 12o*. The synthesis of **12o** was achieved using the method A (as described above), by reaction of the complex (-)-**10a** (1.0 g, 3.5 mmol) with the 3,5-dimethylphenyllithium reagent previously prepared using 1-bromo-3,5-dimethylbenzene (0.95 mL, 7 mmol) in THF (3.5 mL) and *s*-BuLi (1.4 M in cyclohexane, 5.0 mL, 7 mmol). The ring opening product [**11o**] was then trapped by Ph_2PCI . The purification was achieved by column chromatography on silica gel using petroleum ether/toluene (7:3) as eluent. White crystals (0.62 g, 30% yield). $R_f = 0.10$ (petroleum ether/toluene 7:3); Mp = 168-170 °C; $[\alpha]_{\text{D}}^{20} = -78.8$ (c 1.0, CH_2Cl_2). ^1H NMR (500 MHz, CDCl_3): δ 0.50-1.81 (m, 6H), 1.37 (d, $J = 6.2$ Hz, 3H), 2.32 (s, 6H), 2.33 (d, $J = 8.5$ Hz, 3H), 4.58-4.64 (m, 1H), 5.40 (t, $J = 9.2$ Hz, 3H), 6.64-6.68 (m, 2H), 7.09-7.17 (m,

10H), 7.26-7.40 (m, 6H), 7.47-7.54 (m, 3H), 7.73-7.77 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125.8 MHz, CDCl_3): δ 16.3, 21.4, 29.4 (d, $J = 4.5$ Hz), 57.3 (dd, $J = 11.2, 8.8$ Hz), 83.3 (dd, $J = 9.0, 2.5$ Hz), 127.8 (d, $J = 10.6$ Hz), 127.9 (d, $J = 11.1$ Hz), 128.2, 128.5 (d, $J = 9.2$ Hz), 128.6, 128.7, 129.8 (d, $J = 34.2$ Hz), 130.1 (d, $J = 10.3$ Hz), 130.2 (d, $J = 1.9$ Hz), 130.4 (d, $J = 20.4$ Hz), 131.0 (d, $J = 11.2$ Hz), 131.3 (d, $J = 2.2$ Hz), 131.6, 131.7, 131.8 (d, $J = 9.8$ Hz), 132.1 (d, $J = 6.5$ Hz), 132.7, 133.0 (d, $J = 1.6$ Hz), 137.9, 138.1 (d, $J = 5.9$ Hz). $^{31}\text{P}\{^1\text{H}\}$ NMR (202.5 MHz, CDCl_3): δ +71.2 (br.s), +106.8 (br.s). FTIR (neat): ν_{max} 3062-2817, 2394-2249, 1454, 1436, 1222, 1161, 1128, 1108, 1063, 1011, 1000, 991, 958, 894, 864, 855, 769, 761, 753, 736, 712, 691 cm^{-1} . HRMS (ESI/Q-TOF) calcd for $\text{C}_{36}\text{H}_{42}\text{B}_2\text{NOP}_2$ $[\text{M}-\text{H}]^+$: 588.2928; found 588.2934. Anal. calcd for $\text{C}_{36}\text{H}_{43}\text{B}_2\text{NOP}_2$: C 73.37, H 7.35, N 2.38; found: C 73.26, H 7.46, N 2.43.

4.4.7. *(R_p)-(-)-N-[(1R,2S)-2-(Diphenylphosphinito-borane)-1-methyl-2-phenylethyl], N-methyl amino(3,5-di-*t*-butylphenyl)phenylphosphine-borane 12p*. The synthesis of **12p** was achieved using the method A (as described above), by reaction of the complex (-)-**10a** (1.0 g, 3.5 mmol) with the 3,5-di-*t*-butylphenyllithium previously prepared from 1-bromo-3,5-di-*t*-butylbenzene (1.9 g, 7 mmol) in THF (3.5 mL) and *t*BuLi (1.9 M in hexane, 7.4 mL, 14 mmol). The ring opening product [**11p**] was then trapped by Ph_2PCl . The purification was achieved by column chromatography on silica gel using petroleum ether/ CH_2Cl_2 (2:1) as

1 eluent. White solid (1.67 g, 71% yield). $R_f = 0.68$ (petroleum ether/ CH_2Cl_2 2:1); $[\alpha]_D^{20} = -$
2
3
4 63.4 (c 0.4, CHCl_3). ^1H NMR (500 MHz, CDCl_3): δ 0.59-1.52 (m, 6H), 1.30 (s, 18H), 1.42
5
6
7 (d, $J = 6.7$ Hz, 3H), 2.30 (d, $J = 7.5$ Hz, 3H), 4.66-4.72 (m, 1H), 5.42 (t, $J = 9.6$ Hz, 1H),
8
9
10
11 6.67-6.71 (m, 2H), 7.08-7.20 (m, 7H), 7.28-7.36 (m, 4H), 7.40-7.42 (m, 4H), 7.48-7.54 (m,
12
13
14 4H), 7.75-7.78 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125.8 MHz, CDCl_3): δ 16.1, 29.3 (d, $J = 4.4$ Hz),
15
16
17 31.3, 35.0, 57.4 (t, $J = 9.7$ Hz), 83.2 (d, $J = 7.3$ Hz), 124.9, 126.8 (d, $J = 11.9$ Hz), 127.8,
18
19
20
21 127.9 (d, $J = 1.2$ Hz), 128.2, 128.4, 128.5 (d, $J = 10.8$ Hz), 128.8, 129.3 (d, $J = 58.6$ Hz),
22
23
24
25 130.1 (d, $J = 70.6$ Hz), 130.2, 131.1 (d, $J = 11.0$ Hz), 131.3, 131.6-131.7 (m), 131.8, 132.2
26
27
28 (d, $J = 8.8$ Hz), 132.8, 138.2, 150.7 (d, $J = 9.6$ Hz). $^{31}\text{P}\{^1\text{H}\}$ NMR (202.5 MHz, CDCl_3): δ
29
30
31 +72.6 (br.s), +106.9 (br.s). FTIR (neat): ν_{max} 3070-2810, 2391, 2375, 2339, 1585, 1573,
32
33
34
35 1473, 1435, 1242, 1163, 1153, 1100, 1088, 999, 965, 873, 797 cm^{-1} . HRMS (ESI/Q-TOF)
36
37
38
39 calcd for $\text{C}_{42}\text{H}_{55}\text{B}_2\text{NOP}_2\text{Na}$ $[\text{M}+\text{Na}]^+$: 696.3854; found: 696.3834.

40
41
42 4.4.8. (R_p) -(-)- N -[$(1R,2S)$ -2-(Diphenylphosphinito-borane)-1-methyl-2-phenylethyl], N -
43
44
45 methyl amino(3,5-di-*t*-butyl-4-methoxyphenyl)phenylphosphine-borane **12q**. The synthesis
46
47
48
49 of **12q** was achieved using the method A (as described above), by reaction of the complex
50
51
52 (-)-**10a** (1.0 g, 3.5 mmol) with the 3,5-di-*t*-butyl-4-methoxyphenyllithium previously prepared
53
54
55
56 from bromo-3,5-di(*t*-butyl)-4-methoxybenzene (2.1 g, 7 mmol) in THF (3.5 mL) and *s*-BuLi
57
58
59 (1.4 M in hexane, 5.0 mL, 7 mmol). The ring opening product [**11q**] was then trapped by
60

Ph₂PCI. The purification was performed by column chromatography on silica gel using petroleum ether/toluene (7:3) as eluent. White solid (0.49 g, 20% yield). $R_f = 0.10$ (petroleum ether/toluene 7:3); Mp = 166-168 °C; $[\alpha]_D^{20} = -75.3$ (c 1.1, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 0.48-1.78 (m, 6H), 1.37 (s, 18H), 1.39 (d, $J = 6.8$ Hz, 3H), 2.28 (d, $J = 8.0$ Hz, 3H), 3.72 (s, 3H), 4.62-4.69 (m, 1H), 5.39 (t, $J = 9.4$ Hz, 1H), 6.64-6.68 (m, 2H), 7.06-7.18 (m, 7H), 7.27-7.34 (m, 4H), 7.38-7.43 (m, 4H), 7.47-7.54 (m, 3H), 7.73-7.77 (m, 2H). ¹³C{¹H} NMR (125.8 MHz, CDCl₃): δ 16.2, 29.2 (d, $J = 4.7$ Hz), 31.9, 36.0, 57.3 (dd, $J = 11.1, 9.4$ Hz), 64.3, 83.3 (dd, $J = 8.7, 2.5$ Hz), 123.5 (d, $J = 61.9$ Hz), 127.8 (d, $J = 9.9$ Hz), 128.2, 128.4, 128.6 (d, $J = 9.9$ Hz), 128.7, 130.1 (d, $J = 71.8$ Hz), 130.2 (d, $J = 2.2$ Hz), 131.1 (d, $J = 11.1$ Hz), 131.2 (d, $J = 12.1$ Hz), 131.4 (d, $J = 1.9$ Hz), 131.6-131.7 (m), 132.1 (d, $J = 10.2$ Hz), 132.7, 138.1, 143.7 (d, $J = 10.4$ Hz), 161.9 (d, $J = 2.5$ Hz). ³¹P{¹H} NMR (202.5 MHz, CDCl₃): δ +71.6 (br.s), +106.9 (br.s). FTIR (neat): ν_{\max} 3059-3008, 2981-2869, 2375, 2344, 1455, 1437, 1410, 1395, 1264, 1230, 1144, 1118, 1065, 1011, 999, 972, 962, 893, 870, 768, 758, 739, 714, 698, 690 cm⁻¹. HRMS (ESI/Q-TOF) calcd for C₄₃H₅₆B₂P₂NO₂ [M-H]⁺: 702.3972; found 702.3979. Anal. calcd for C₄₃H₅₇B₂NO₂P₂: C 73.41, H 8.17, N 1.99; found: C 73.72, H 8.16, N 2.09.

4.4.9. (*R_p*)-(-)-*N*-[(1*R*,2*S*)-2-(Diphenylphosphinito-borane)-1-methyl-2-phenylethyl], *N*-(methyl amino)phenyl(2-pyridyl)phosphine-borane **12r**. The synthesis of **12r** was achieved

1 using the method A (as described above), by reaction of the complex (-)-**10a** (1.0 g, 3.5
2
3
4 mmol) previously prepared from 2-bromopyridine (1.1 g, 7 mmol) and *s*-BuLi (1.4 M in
5
6
7 cyclohexane, 5.0 mL, 7 mmol). The ring opening product [**11r**] was then trapped by
8
9
10 Ph₂PCI. The purification was performed by column chromatography on silica gel using
11
12 toluene as eluent. White crystals (1.06 g, 54% yield). $R_f = 0.15$ (toluene); Mp = 178-180 °C;
13
14
15 $[\alpha]_D^{20} = -40.2$ (c 1.1, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ 0.20-1.60 (m, 6H), 1.32 (d, $J =$
16
17
18 6.5 Hz, 3H), 2.49 (d, $J = 7.3$ Hz, 3H), 4.56-4.65 (m, 1H), 5.42 (t, $J = 9.3$ Hz, 1H), 6.52-6.59
19
20
21 (m, 2H), 7.00-7.50 (m, 18H), 7.74-7.85 (m, 3H), 7.98-8.00 (m, 1H), 8.73-8.74 (m, 1H).
22
23
24
25
26
27
28 ¹³C{¹H} NMR (75.5 MHz, CDCl₃): δ 16.3, 29.8 (d, $J = 5.0$ Hz), 57.5 (dd, $J = 10.7, 8.7$ Hz),
29
30
31 83.2 (dd, $J = 7.3, 2.5$ Hz), 124.9 (d, $J = 2.0$ Hz), 128.0, 128.1 (d, $J = 4.2$ Hz), 128.2, 128.3,
32
33
34 128.6 (d, $J = 5.4$ Hz), 128.6, 129.0, 129.1 (d, $J = 26.5$ Hz), 129.9 (d, $J = 75.8$ Hz), 130.6 (d,
35
36
37 $J = 2.5$ Hz), 131.2 (d, $J = 11.3$ Hz), 131.5 (d, $J = 2.4$ Hz), 131.7, 131.8 (d, $J = 2.5$ Hz),
38
39
40 131.9 (d, $J = 38.7$ Hz), 132.7 (d, $J = 51.9$ Hz), 136.1 (d, $J = 9.4$ Hz), 138.2, 150.0 (d, $J =$
41
42
43 12.7 Hz). ³¹P{¹H} NMR (121.5 MHz, CDCl₃): δ 72.1 (br.s), 106.6 (br.s). FTIR (neat): ν_{max}
44
45
46 3061-2934, 2387, 2345, 1455, 1437, 1421, 1133, 1113, 1062, 1010, 977, 895, 739, 721,
47
48
49 691 cm⁻¹. Anal. calcd for C₃₃H₃₈B₂N₂OP₂: C 70.50, H 6.81, N 4.98; found: C 70.60, H 6.94,
50
51
52
53
54
55
56 N 5.20.
57
58
59
60

4.4.10. (*R_p*)-(-)-*N*-[(1*R*,2*S*)-2-(Diphenylphosphinito-borane)-1-methyl-2-phenylethyl], *N*-methyl amino-2-(2',6'-dimethoxy-1,1'-biphenyl)phenylphosphine-borane **12s**. The synthesis of **12s** was achieved using the method A (as described above), by reaction of the complex (-)-**10a** (1.0 g, 3.5 mmol) with the 2',6'-dimethoxy-1,1'-biphenyllithium previously prepared from 2-bromo-2',6'-dimethoxy-1,1'-biphenyl (2.1 g, 7 mmol) in THF (3.5 mL) and *t*BuLi (1.9 M in hexane, 7.4 mL, 14 mmol). The ring opening product [**11s**] was then trapped by Ph₂PCl. The purification was achieved by column chromatography on silica gel using petroleum ether/CH₂Cl₂ (2:1) as eluent. White solid (1.00 g, 41% yield). *R_f* = 0.47 (petroleum ether/CH₂Cl₂ 2:1); [α]_D²⁰ = -23.3 (c 0.3, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 0.20-1.69 (m, 6H), 1.33 (d, *J* = 6.1 Hz, 3H), 2.49 (d, *J* = 7.6 Hz, 3H), 3.38 (s, 3H), 3.64 (s, 3H), 4.28-4.34 (m, 1H), 5.37-5.40 (m, 1H), 6.23 (d, *J* = 8.1 Hz, 1H), 6.38 (d, *J* = 8.1 Hz, 1H), 6.90-7.00 (m, 7H), 7.08-7.17 (m, 7H), 7.24-7.32 (m, 4H), 7.38-7.54 (m, 5H), 7.71-7.75 (m, 2H). ¹³C{¹H} NMR (125.8 MHz, CDCl₃): δ 14.8, 30.4 (d, *J* = 2.4 Hz), 54.8, 55.1, 57.3 (t, *J* = 9.2 Hz), 83.8 (dd, *J* = 2.9, 6.4 Hz), 103.0 (d, *J* = 17.4 Hz), 117.8 (d, *J* = 3.2 Hz), 126.5 (d, *J* = 9.2 Hz), 127.3 (d, *J* = 10.3 Hz), 127.7, 127.8 (d, *J* = 10.3 Hz), 128.2, 128.3, 128.5 (d, *J* = 10.3 Hz), 129.3, 129.8 (d, *J* = 2.0 Hz), 130.5 (d, *J* = 59.0 Hz), 130.6 (d, *J* = 1.8 Hz), 131.1 (d, *J* = 11.6 Hz), 131.3 (d, *J* = 1.8 Hz), 131.5, 131.6 (2s), 131.7, 131.8, 132.1 (d, *J* = 28.5 Hz), 132.7 (d, *J* = 36.2 Hz), 133.2 (d, *J* = 8.8 Hz), 133.9 (d, *J* = 7.8 Hz), 138.0, 140.0

(d, $J = 12.0$ Hz), 157.6, 157.8. $^{31}\text{P}\{^1\text{H}\}$ NMR (202.5 MHz, CDCl_3): δ +72.1 (br.s), +106.0-106.2 (m). FTIR (neat): ν_{max} 3075-2820, 2380, 2369, 2337, 1583, 1476, 1436, 1242, 1164, 1100, 1086, 998, 963, 870, 795, 738, 718 cm^{-1} . HRMS (ESI/Q-TOF) calcd for $\text{C}_{42}\text{H}_{47}\text{B}_2\text{P}_2\text{NO}_3\text{Na}$ $[\text{M}+\text{Na}]^+$: 720.3144; found: 720.3109.

4.4.11. (R_p)-(-)-*N*-[(1*R*,2*S*)-(2-(*Di*- α -naphthylphosphinito-borane)-1-methyl-2-phenylethyl)], *N*-methylamino(*o*-biphenyl)phenylphosphine-borane **12t**. The synthesis of the **12t** was achieved using the method A (as described above) by reaction of the complex (-)-**10a** (1.0 g, 3.5 mmol) with the 1,1'-biphenyllithium previously prepared from 2-bromo-1,1'-biphenyl (1.3 mL, 7 mmol) in THF (3.5 mL) and *s*-BuLi (1.4 M in cyclohexane, 5.0 mL, 7 mmol). The ring opening product [**11t**] was then trapped by α - Np_2PCl . The purification was achieved by column chromatography on silica gel using petroleum ether/ CH_2Cl_2 (2:1) as eluent. White solid (1.65 g, 64% yield). $R_f = 0.27$ (petroleum ether/ CH_2Cl_2 , 2:1); $[\alpha]_{\text{D}}^{20} -93.2$ (c 0.3, CHCl_3). ^1H NMR (500 MHz, CDCl_3): δ 0.50-1.82 (m, 6H), 1.37 (d, $J = 6.9$ Hz, 3H), 2.45 (d, $J = 6.9$ Hz, 3H), 4.55-4.58 (m, 1H), 5.47 (t, $J = 8.2$ Hz, 1H), 6.39 (t, $J = 7.7$ Hz, 2H), 6.53 (t, $J = 7.4$ Hz, 1H), 6.83-6.87 (m, 6H), 6.98-7.08 (m, 7H), 7.16-7.27 (m, 4H), 7.35-7.38 (m, 2H), 7.41-7.44 (m, 2H), 7.57 (d, $J = 8.3$ Hz), 7.65-7.75 (m, 3H), 7.80 (d, $J = 8.3$ Hz, 1H), 7.94 (d, $J = 8.3$ Hz, 1H), 8.01 (d, $J = 7.8$ Hz, 1H), 8.11 (dd, $J = 15.6, 6.4$ Hz, 1H), 8.38 (ddd, $J = 13.0, 7.2, 1.0$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125.8 MHz, CDCl_3): δ 15.8 (d, $J = 1.6$ Hz),

29.9 (d, $J = 3.1$ Hz), 57.7 (t, $J = 10.2$ Hz), 82.9 (dd, $J = 4.9, 3.0$ Hz), 124.2 (d, $J = 15.8$ Hz),
124.9 (d, $J = 9.5$ Hz), 125.7, 125.9 (d, $J = 6.3$ Hz), 126.0, 126.1, 126.4 (d, $J = 10.1$ Hz),
126.8, 126.9, 127.0, 127.5 (d, $J = 10.8$ Hz), 127.9, 128.4 (d, $J = 51.2$ Hz), 128.5, 128.8 (d,
 $J = 4.2$ Hz), 128.9, 129.3 (d, $J = 9.5$ Hz), 129.8 (d, $J = 1.8$ Hz), 129.9, 130.3 (d, $J = 1.8$ Hz),
130.8 (d, $J = 62.4$ Hz), 131.7 (d, $J = 8.9$ Hz), 131.8, 131.9, 132.1 (d, $J = 11.3$ Hz), 132.3 (d,
 $J = 3.6$ Hz), 132.7, 132.8 (d, $J = 2.6$ Hz), 132.9, 133.2-133.3 (m), 133.6 (d, $J = 8.2$ Hz),
133.6 (d, $J = 8.2$ Hz), 134.5, 134.6, 136.4, 140.7 (d, $J = 2.7$ Hz), 147.0 (d, $J = 9.5$ Hz).

$^{31}\text{P}\{^1\text{H}\}$ NMR (202.5 MHz, CDCl_3): δ +71.3 (br.s), +106.5 (br.s). FTIR (neat): ν_{max} 3057-
2807, 2393, 2375, 2345, 1579, 1475, 1437, 1242, 1163, 1099, 1086, 999, 965, 871, 798
 cm^{-1} . HRMS (ESI/Q-TOF) calcd for $\text{C}_{48}\text{H}_{47}\text{B}_2\text{NOP}_2\text{Na}$ $[\text{M}+\text{Na}]^+$: 760.3211; found: 760.3226.

4.4.12. *(M,S_p)-(+)-N-[(1S,2R)-2-(Diphenylphosphinito-borane)-1-methyl-2-phenylethyl],
N-methylamino-2-(1,1'-binaphthyl)phenylphosphine-borane 12v*. The synthesis of **12v** was
achieved using the method B (as described above) by reaction of the aminophosphine-
borane **11v** (0.30 g, 0.56 mmol) with *n*-BuLi (1.6 M in hexane (0.42 mL, 0.67 mmol), then
with Ph_2PCl (0.20 mL, 1.12 mmol) and borane-dimethyl sulfide (0.42 mL, 4.48 mmol). The
purification was achieved by chromatography on silica gel using petroleum ether/ CH_2Cl_2
(1:1) as eluent to afford AMPP*-diborane **12v** as a white solid (0.17 g, 41% yield). $R_f = 0.33$
(petroleum ether/ CH_2Cl_2 1:1); $[\alpha]_{\text{D}}^{20} = +10.6$ (c 0.8, CHCl_3). ^1H NMR (500 MHz, CDCl_3): δ

0.19-1.20 (m, 6H), 1.14 (d, $J = 6.4$ Hz, 3H), 2.55 (d, $J = 7.4$ Hz), 4.15-4.22 (m, 1H), 5.36 (t, $J = 9.1$ Hz, 1H), 6.81-6.93 (m, 9H), 7.02-7.09 (m, 6H), 7.14-7.25 (m, 6H), 7.38-7.41 (m, 1H), 7.43-7.52 (m, 4H), 7.64-7.70 (m, 4H), 7.75 (d, $J = 8.2$ Hz, 1H), 7.89-7.92 (m, 2H).

$^{13}\text{C}\{^1\text{H}\}$ NMR (125.8 MHz, CDCl_3): δ 14.4, 31.2 (d, $J = 1.5$ Hz), 57.6 (t, $J = 9.0$ Hz), 83.7 (dd, $J = 5.5, 2.9$ Hz), 124.6, 125.6, 125.8, 126.6, 127.0, 127.2 (d, $J = 9.6$ Hz), 127.5 (d, $J = 2.9$ Hz), 127.6, 127.7, 127.8, 127.9 (d, $J = 5.0$ Hz), 128.1, 128.2, 128.5 (d, $J = 2.7$ Hz), 128.6, 128.7 (d, $J = 11.2$ Hz), 129.1, 129.8 (d, $J = 2.3$ Hz), 131.0, 131.1, 131.3 (d, $J = 1.8$ Hz), 131.4, 131.5, 131.6 (2s), 131.7 (d, $J = 15.6$ Hz), 132.1 (d, $J = 9.2$ Hz), 132.3, 132.6, 133.1, 133.6, 133.9 (d, $J = 9.6$ Hz), 134.0 (d, $J = 1.6$ Hz), 134.6 (d, $J = 4.3$ Hz), 137.9, 143.7 (d, $J = 10.6$ Hz); $^{31}\text{P}\{^1\text{H}\}$ NMR (202.5 MHz, CDCl_3): δ +73.4 (br.s), +106.0 (br.s).

FTIR (neat): ν_{max} 3073-2820, 2390, 2372, 2342, 1580, 1571, 1470, 1435, 1240, 1160, 1151, 1101, 1090, 997, 963, 870, 795, 740, 721 cm^{-1} . HRMS (ESI/Q-TOF) calcd for $\text{C}_{48}\text{H}_{45}\text{BNOP}_2$ $[\text{M}-\text{BH}_3+\text{H}]^+$: 724.3097; found 724.3064.

4.4.13. (S_p)-(+)-*N*-[(1*S*,2*R*)-2-[Bis(3,5-dimethylphenyl)phosphinito-borane]-1-methyl-2-phenylethyl], *N*-methylamino(*o*-biphenyl)phenylphosphine-borane **12w**. This compound was synthesized using the method A (as described above) by reaction of the complex (+)-**10a** (1.0 g, 3.5 mmol) prepared from (-)-ephedrine **9**, with the α -biphenyllithium reagent previously prepared from 2-bromo-1,1'-biphenyl (1.2 mL, 7 mmol) in THF (3.5 mL) and *s*-

BuLi (1.4 M in cyclohexane, 5 mL, 7 mmol). The ring-opening product **[11w]** was then trapped with chloro-bis(3,5-dimethylphenyl)phosphine (3,5-Xyl)₂PCl (1.9 g, 7 mmol). The purification was achieved by chromatography on silica gel using petroleum ether/CH₂Cl₂ (2:1) as eluent to afford the AMPP*-diborane **12w** as a white sticky solid (1.02 g, 42% yield); *R*_f = 0.24 (petroleum ether/CH₂Cl₂ 2:1); [α]_D²⁰ = +85.5 (c 0.3, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 0.50-1.52 (m, 6H), 1.26 (d, *J* = 6.8 Hz, 3H), 2.05 (s, 6H), 2.37 (s, 6H), 2.44 (d, *J* = 6.5 Hz, 3H), 4.44-4.50 (m, 1H), 5.21 (t, *J* = 9.2 Hz, 1H), 6.74 (d, *J* = 9.5 Hz, 2H), 6.82-6.85 (m, 3H), 6.90-7.18 (m, 14H), 7.31 (d, *J* = 5.5 Hz, 2H), 7.36-7.40 (m, 1H), 7.44-7.52 (m, 3H). ¹³C{¹H} NMR (125.8 MHz, CDCl₃): δ 15.2 (d, *J* = 1.9 Hz), 21.0, 21.4, 30.0 (d, *J* = 3.5 Hz), 57.8 (dd, *J* = 9.9, 8.4 Hz), 82.8 (dd, *J* = 4.2, 3.1 Hz), 115.8, 120.8, 126.9, 127.0 (2s), 127.5, 127.6 (d, *J* = 10.9 Hz), 128.1, 128.2, 128.6 (d, *J* = 11.4 Hz), 129.0 (d, *J* = 62.0 Hz), 129.1 (d, *J* = 11.3 Hz), 129.9, 130.3 (d, *J* = 1.5 Hz), 130.9 (d, *J* = 62.5 Hz), 131.5, 131.9, 132.0, 132.4, 132.8 (d, *J* = 8.1 Hz), 133.0 (d, *J* = 2.5 Hz), 133.3 (d, *J* = 9.1 Hz), 133.4 (d, *J* = 2.0 Hz), 137.3 (d, *J* = 11.3 Hz), 138.0 (d, *J* = 11.9 Hz), 138.1, 140.8 (d, *J* = 2.5 Hz), 147.0 (d, *J* = 8.7 Hz). ³¹P{¹H} NMR (202.5 MHz, CDCl₃): δ +71.1 (br.s), +107.4 (br.s). IR (neat): ν_{max} 3067-2817, 2389, 2370, 2346, 1580, 1473, 1436, 1241, 1162, 1153, 1099, 998, 965, 870, 797 cm⁻¹. HRMS (ESI/Q-TOF) calcd for C₄₄H₅₁B₂NOP₂ [M+Na]⁺: 716.3524; found: 716.3534.

1
2
3
4 **4.5. Typical procedure for the decomplexation of aminophosphine-phosphinite-**
5 **diboranes 12.** A solution of aminophosphine-phosphinite-diborane **12** (1 mmol) and
6
7 DABCO (4 mmol) in toluene (3 mL) was heated at 50°C with an oil bath and was stirred
8
9
10
11 under argon overnight. After removing the solvent under vacuum, the residue was purified
12
13
14 by chromatography on neutral aluminium-oxide using a mixture of petroleum ether/ethyl
15
16
17 acetate (4:1) or toluene as eluent, to afford the free AMPP* **13**.

18
19
20
21 **4.5.1.** The EPHOS **1**^{9a} and the free *o*-anisyl,^{9a} α -naphthyl,^{9a} β -naphthyl,^{9a} *o*-biphenyl,^{9b}
22
23
24
25 *ferrocenyl*,^{9b} *t*-butyl,^{9a} *methyl*,^{9a,10a} *cyclohexyl*,^{9b} *o*-[(2-methoxyethoxy)methoxy]phenyl,^{9b}
26
27
28
29 *calixarenyl*,^{9c} AMPP* ligands **13a-c**, **13f-h**, **13j-l** and **13u**, respectively, were prepared and
30
31
32 characterized according to described procedures.

33
34
35 **4.5.2.** (*S_p*)-(-)-*N*-[(1*R*,2*S*)-2-(Diphenylphosphinito)-1-methyl-2-phenyl]ethyl], *N*-methyl
36
37
38
39 *amino(o-biphenyl)phenylphosphine 13i*. ³¹P{¹H} NMR (121.5 MHz, CD₂Cl₂): δ +60.2,
40
41
42 +108.7.

43
44
45 **4.5.3.** (*R_p*)-*N*-[(1*R*,2*S*)-2-(Diphenylphosphinito)-1-methyl-2-phenylethyl], *N*-
46
47
48
49 *methylamino(2-isopropoxyphenyl)phenylphosphine 13m*. ³¹P{¹H} NMR (121.5 MHz,
50
51
52 CDCl₃): δ +54.7, +111.7.

1 4.5.4. (*R_p*)-*N*-[(1*R*,2*S*)-2-(Diphenylphosphinito)-1-methyl-2-phenylethyl], *N*-

2
3
4 methylamino(2-benzyloxyphenyl)phenylphosphine **13n**. ³¹P{¹H} NMR (121.5 MHz, CDCl₃):

5
6
7 δ +53.1, +111.1.

8
9
10 4.5.5. (*R_p*)-*N*-[(1*R*,2*S*)-2-(Diphenylphosphinito)-1-methyl-2-phenylethyl], *N*-methylamino

11
12
13 (3,5-dimethylphenyl)phenylphosphine **13o**. ³¹P{¹H} NMR (202.5 MHz, CDCl₃): δ +61.4,

14
15
16
17 +110.6.

18
19
20 4.5.6. (*R_p*)-*N*-[(1*R*,2*S*)-2-(Diphenylphosphinito)-1-methyl-2-phenylethyl], *N*-

21
22
23 methylamino(3,5-di-*t*-butylphenyl)phenylphosphine **13p**. ³¹P{¹H} NMR (121.5 MHz, CDCl₃):

24
25
26
27
28 δ +68.6, +110.4.

29
30
31 4.5.7. (*R_p*)-*N*-[(1*R*,2*S*)-2-(Diphenylphosphinito)-1-methyl-2-phenylethyl], *N*-methylamino

32
33
34 (3,5-di-*t*-butyl-4-methoxyphenyl)phenylphosphine **13q**. ³¹P{¹H} NMR (121.5 MHz, CDCl₃): δ

35
36
37
38 +67.8, +111.5.

39
40
41 4.5.8. (*R_p*)-*N*-[(1*R*,2*S*)-2-(Diphenylphosphinito)-1-methyl-2-phenylethyl], *N*-

42
43
44 (methylamino) phenyl(2-pyridyl)phosphine **13r**. ³¹P{¹H} NMR (202.5 MHz, CDCl₃): δ +61.3,

45
46
47
48 +111.8.

49
50
51 4.5.9. (*R_p*)-*N*-[(1*R*,2*S*)-2-(Diphenylphosphinito)-1-methyl-2-phenylethyl], *N*-methylamino-

52
53
54 2-(2',6'-dimethoxy-1,1'-biphenyl)phenylphosphine **13s**. ³¹P{¹H} NMR (121.5 MHz, CDCl₃): δ

55
56
57
58 +56.5, +110.1.

1 4.5.10. (*R_p*)-*N*-[(1*R*,2*S*)-2-(*Di-α*-naphthylphosphinito)-1-methyl-2-phenylethyl], *N*-
2
3
4 methylamino (*o*-biphenyl)phenylphosphine **13t**. ³¹P{¹H} NMR (121.5 MHz, CDCl₃): δ +56.0,
5
6
7 +97.2.
8
9

10 4.5.11. (*M,S_p*)-(+)-*N*-[(1*S*,2*R*)-2-(Diphenylphosphinito)-1-methyl-2-phenylethyl], *N*-
11
12 methylamino-2-(1,1'-binaphthyl)phenylphosphine **13v**. ³¹P{¹H} NMR (202.5 MHz, CDCl₃): δ
13
14 +53.8, +109.9.
15
16
17
18
19

20 4.5.12. (*S_p*)-*N*-[(1*S*,2*R*)-2-Bis(3,5-dimethylphenyl)phosphinito]-1-methyl-2-phenylethyl],
21
22 *N*-methyl amino(*o*-biphenyl)phenylphosphine-borane **13w**. ³¹P{¹H} NMR (121.5 MHz,
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
21

1 4.7.1. *Typical procedure.*¹² To a solution of the aminophosphine-borane **11** (1 mmol) in
2
3
4 toluene (3 mL) was added 0.6 mmol (2.0 mmol for **11** with R¹ = alkyl) of DABCO. The
5
6
7 solution was heated at 50°C with an oil bath and was stirred overnight.
8
9
10 Chlorodiphenylphosphine (2 mmol) and triethylamine (5 mmol) were added at room
11
12 temperature. The solution was stirred for 4 h before addition of BH₃.DMS (8 mmol) at 0 °C
13
14 and the mixture was again stirred for 4 h. After hydrolysis, the aqueous phase was
15
16 extracted with dichloromethane and the organic phase was washed with saturated NaCl
17
18 solution, dried over MgSO₄ and evaporated. The residue was purified by chromatography
19
20 on silica gel with toluene as eluent to afford the AMPP*(BH₃)₂ **21** which was recrystallized
21
22 in a mixture of hexane/CH₂Cl₂.
23
24
25
26
27
28
29
30
31
32
33

34
35 4.7.2. (*S_p*)-(+)-*N*-[(1*S*,2*R*)-2-(*o*-Anisylphenylphosphinito-borane)-1-methyl-2-phenylethyl],
36
37
38 *N*-methylaminodiphenylphosphine-borane **21a**. This compound was synthesized from (*S_p*)-
39
40 (+)-*N*-[(1*S*,2*R*)-2-hydroxy-1-methyl-2-phenylethyl], *N*-methylamino(*o*-anisyl)phenyl
41
42
43
44
45
46 phosphine-borane **11a** previously prepared from (-)-ephedrine **9**.^{11b} X-ray quality crystals
47
48 were grown by slow evaporation of CH₂Cl₂; The structure and the data were reported in the
49
50 SI. White crystalline needles (0.38 g, 65% yield); *R_f* = 0.60 (toluene); Mp = 155 °C. [α]_D²⁰ =
51
52 +68.8 (c 0.6, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 0.34-1.45 (m, 6H), 1.26 (d, *J* = 6.6 Hz,
53
54 3H), 2.21 (d, *J* = 7.6 Hz, 3H), 3.47 (s, 3H), 4.47-4.57 (m, 1H), 5.33 (t, *J* = 9.4 Hz, 1H), 6.51-
55
56
57
58
59
60

6.58 (m, 2H), 6.77 (dd, $J = 8.2, 4.6$ Hz, 1H), 6.95-7.09 (m, 8H), 7.10-7.15 (m, 1H), 7.16-7.34 (m, 7H), 7.35-7.50 (m, 4H), 7.80 (ddd, $J = 11.9, 7.0, 1.7$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR: (125.8 MHz, CDCl_3): δ 16.0, 29.4 (d, $J = 4.5$ Hz), 55.5, 57.6 (dd, $J = 11.1, 8.6$ Hz), 82.4 (dd, $J = 8.9, 2.5$ Hz), 111.8 (d, $J = 5.2$ Hz), 120.2 (d, $J = 70.2$ Hz), 120.8 (d, $J = 10.5$ Hz), 127.4 (d, $J = 10.9$ Hz), 128.0 (d, $J = 10.9$ Hz), 128.1, 128.3 (d, $J = 8.4$ Hz), 128.4, 128.7, 129.7 (d, $J = 71.7$ Hz), 130.3 (d, $J = 2.4$ Hz), 130.6 (d, $J = 2.2$ Hz), 130.7 (d, $J = 57.3$ Hz), 131.0, 131.7 (d, $J = 10.5$ Hz), 132.5 (d, $J = 10.2$ Hz), 132.6 (d, $J = 62.4$ Hz), 133.3 (d, $J = 9.3$ Hz), 133.9 (d, $J = 2.0$ Hz), 138.4, 160.9 (d, $J = 4.4$ Hz). $^{31}\text{P}\{^1\text{H}\}$ NMR (202.5 MHz, CDCl_3): δ +71.1 (br.s), +105.3 (br.s). HRMS (ESI/Q-TOF) calcd for $\text{C}_{35}\text{H}_{41}\text{B}_2\text{NO}_2\text{P}_2\text{Na}$ $[\text{M}+\text{Na}]^+$: 614.27026; found 614.26804. Anal. calcd for $\text{C}_{35}\text{H}_{41}\text{B}_2\text{NO}_2\text{P}_2$: C 71.10, H 6.99, N 2.37; found: C 70.76, H 7.02, N 2.46.

4.7.3. *(R_p)-(+)-N-[(1R,2S)-2-(*o*-Anisylphenylphosphinito-borane)-1-methyl-2-phenylethyl], N-methylaminodiphenylphosphine-borane 21a.* This enantiomer was synthesized from *(R_p)-(+)-N-[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl], N-methylamino(*o*-anisyl)phenyl phosphine-borane 11a* previously prepared from (+)-ephedrine **9**.^{11b} (0.40 g, 68% yield). $^{31}\text{P}\{^1\text{H}\}$ NMR (202.5 MHz, CDCl_3): δ +71.3 (br.s), +105.1 (br.s).

4.7.4. *(S_p)-(+)-N-[(1S,2R)-2-(α -Naphthylphenylphosphinito-borane)-1-methyl-2-phenylethyl], N-methylaminodiphenylphosphine-borane 21b.* This compound was

1 synthesized from (*S_p*)-(+)-*N*-[(1*S*,2*R*)-2-hydroxy-1-methyl-2-phenylethyl], *N*-methylamino(*α*-
2
3
4 *naphthyl*)phenylphosphine-borane **11c** previously prepared from (-)-ephedrine **9**.^{11b,29} X-ray
5
6
7 quality crystals were grown by slow evaporation of CH₂Cl₂. The structure and the data
8
9
10 were reported in the SI. Colorless crystals (0.37 g, 61% yield); *R*_f = 0.60 (toluene); Mp =
11
12
13 198 °C. [α]_D²⁰ = +48.9 (c 0.5, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 0.38-1.61 (m, 6H), 1.02
14
15 (d, *J* = 6.6 Hz, 3H), 2.19 (d, *J* = 7.6 Hz, 3H), 4.42-4.54 (m, 1H), 5.51 (t, *J* = 9.7 Hz, 1H),
16
17
18 6.56 (dd, *J* = 11.3, 7.8 Hz, 2H), 6.93-7.02 (m, 4H), 7.03- 7.21 (m, 8H), 7.22-7.45 (m, 8H),
19
20
21 7.49-7.54 (m, 1H), 7.77 (d, *J* = 8.2 Hz, 1H), 7.94 (d, *J* = 8.5 Hz, 2H), 8.31 (ddd, *J* = 14.8,
22
23
24 7.1, 0.7 Hz, 1H). ¹³C{¹H} NMR (125.8 MHz, CDCl₃): δ 16.0, 29.4 (d, *J* = 4.5 Hz), 57.5 (dd, *J*
25
26
27 = 11.2, 7.7 Hz), 83.6 (dd, *J* = 8.9, 3.0 Hz), 124.7 (d, *J* = 13.5 Hz), 126.3, 126.8 (d, *J* = 5.0
28
29
30 Hz), 127.1, 127.7 (d, *J* = 63.7 Hz), 128.0 (d, *J* = 5.7 Hz), 128.1 (d, *J* = 6.1 Hz), 128.3,
31
32
33 128.4, 128.6, 128.9, 129.0, 129.7 (d, *J* = 71.6 Hz), 130.4 (d, *J* = 2.0 Hz), 130.9, 130.9 (d, *J*
34
35
36 = 11.8 Hz), 131.1 (d, *J* = 1.7 Hz), 131.7 (d, *J* = 10.3 Hz), 132.3 (d, *J* = 6.4 Hz), 132.5 (d, *J* =
37
38
39 10.2 Hz), 133.0 (d, *J* = 63.3 Hz), 133.5 (d, *J* = 2.4 Hz), 133.8 (d, *J* = 7.6 Hz), 133.9, 134.0,
40
41
42 138.5. ³¹P{¹H} NMR (202.5 MHz, CDCl₃): δ +71.3 (br.s), +110.0 (br.s). HRMS (ESI/Q-TOF)
43
44
45 calcd for C₃₈H₄₁B₂NOP₂Na [M+Na]⁺: 634.27472; found: 634.27398. HRMS (ESI/Q-TOF)
46
47
48 calcd for C₃₈H₄₂B₂NOP₂ [M+H]⁺: 612.29278; found: 612.29213.
49
50
51
52
53
54
55
56
57
58
59
60

1 4.7.5. (R_p) -(+)-*N*-[(1*R*,2*S*)-2-(α -Naphthylphenylphosphinito-borane)-1-methyl-2-
2 phenylethyl], *N*-methylaminodiphenylphosphine-borane **21b**. This enantiomer was
3
4 synthesized from (R_p) -(+)-*N*-[(1*R*,2*S*)-2-hydroxy-1-methyl-2-phenylethyl], *N*-methylamino(α -
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
naphthyl)phenylphosphine-borane **11c** previously prepared from (+)-ephedrine **9**.^{11b,29} (0.39
g, 63% yield). ³¹P{¹H} NMR (202.5 MHz, CDCl₃): δ +71.5 (br.s), +110.2 (br.s).

18 4.7.6. (R_p) -(-)-*N*-[(1*R*,2*S*)-2-(β -Naphthylphenylphosphinito-borane)-1-methyl-2-
19 phenylethyl], *N*-methylaminodiphenylphosphine-borane **21c**. This compound was
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
synthesized from (R_p) -(-)-*N*-[(1*R*,2*S*)-2-hydroxy-1-methyl-2-phenylethyl], *N*-methylamino(β -
naphthyl)phenylphosphine-borane **11d** previously prepared from (+)-ephedrine **9**.^{11b,29b} X-
ray quality crystals were grown by slow evaporation of cyclohexane. The structure and the
data were reported in the SI. Colorless crystals (0.49 g, 81% yield); *R*_f = 0.60 (toluene); Mp
= 151 °C. [α]_D²⁰ = -66.3 (c 0.6, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ 0.38-1.81 (m, 6H),
1.35 (d, *J* = 6.5 Hz, 3H), 2.33 (d, *J* = 7.5 Hz, 3H), 4.58-4.74 (m, 1H), 5.46 (t, *J* = 9.4 Hz,
1H), 6.59-6.71 (m, 2H), 7.05-7.23 (m, 6H), 7.26-7.66 (m, 14H), 7.68-7.77 (m, 1H), 7.86-
8.00 (m, 3H), 8.33 (d, *J* = 12.7 Hz, 1H). ¹³C{¹H} NMR (75.5 MHz, CDCl₃): δ 16.0, 29.4 (d, *J*
= 4.5 Hz), 57.5 (dd, *J* = 11.2, 8.6 Hz), 83.6 (dd, *J* = 8.8, 3.0 Hz), 126.1 (d, *J* = 10.3 Hz),
126.9, 127.9 (d, *J* = 3.5 Hz), 128.0 (d, *J* = 2.8 Hz), 128.2 (d, *J* = 2.9 Hz), 128.3, 128.4 (d, *J*
= 10.0 Hz), 128.4, 128.6, 128.8, 129.0, 129.2, 130.2 (d, *J* = 7.5 Hz), 130.4 (d, *J* = 2.2 Hz),

1 131.0, 131.2 (d, $J = 2.1$ Hz), 131.4 (d, $J = 2.1$ Hz), 131.5, 131.6 (d, $J = 1.2$ Hz), 131.8,
2
3
4 132.4, 132.5 (d, $J = 10.3$ Hz), 132.6 (d, $J = 18.8$ Hz), 132.8 (d, $J = 12.6$ Hz), 134.6 (d, $J =$
5
6
7 2.3 Hz), 138.1. $^{31}\text{P}\{^1\text{H}\}$ NMR (121.5 MHz, CDCl_3): δ +71.1 (br.s), +107.2 (br.s). HRMS
8
9
10 (ESI/Q-TOF) calcd for $\text{C}_{38}\text{H}_{41}\text{B}_2\text{NOP}_2\text{Na}$ $[\text{M}+\text{Na}]^+$: 634.27472; found: 634.27319.

11
12
13
14 4.7.7. (R_p) -(-)- N -[(1*R*,2*S*)-2-(Phenyl-*o*-tolylphosphinito-borane)-1-methyl-2-phenylethyl],
15
16
17
18 N -methylaminodiphenylphosphine-borane **21d**. This compound was synthesized from (R_p) -
19
20
21 (-)- N -[(1*R*,2*S*)-2-hydroxy-1-methyl-2-phenylethyl], N -methylamino(phenyl-*o*-
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

the SI. Colorless crystals (0.37 g, 65% yield); $R_f = 0.60$ (toluene); Mp = 190 °C. $[\alpha]_D^{20} = -$
59.3 (c 0.5, CHCl_3). ^1H NMR (300 MHz, CDCl_3): δ 0.25-1.66 (m, 6H), 1.17 (d, $J = 6.5$ Hz,
3H), 2.07 (s, 3H), 2.23 (d, $J = 7.6$ Hz, 3H), 4.42-4.62 (m, 1H), 5.43 (t, $J = 9.6$ Hz, 1H), 6.50-
6.60 (m, 2H), 6.95-7.24 (m, 12H), 7.27-7.51 (m, 9H), 8.04 (ddd, $J = 12.5, 7.4, 1.4$ Hz, 1H).
 $^{13}\text{C}\{^1\text{H}\}$ NMR (75.5 MHz, CDCl_3): δ 16.2, 21.6 (d, $J = 4.3$ Hz), 29.4 (d, $J = 4.6$ Hz), 57.4
(dd, $J = 11.2, 7.7$ Hz), 83.1 (dd, $J = 9.3, 2.8$ Hz), 125.7 (d, $J = 11.6$ Hz), 127.9 (d, $J = 3.1$
Hz), 128.1 (d, $J = 3.0$ Hz), 128.3, 128.4 (d, $J = 2.8$ Hz), 128.7, 129.2 (d, $J = 18.6$ Hz), 130.2
(d, $J = 6.8$ Hz), 130.3 (d, $J = 2.4$ Hz), 130.6 (d, $J = 51.9$ Hz), 130.9, 131.0, 131.2 (d, $J = 2.1$
Hz), 131.7, 131.7 (d, $J = 10.2$ Hz), 132.1 (d, $J = 2.3$ Hz), 132.6 (d, $J = 61.6$ Hz), 132.5 (d, J

= 10.4 Hz), 132.9 (d, $J = 14.2$ Hz), 138.4, 141.5 (d, $J = 8.8$ Hz). $^{31}\text{P}\{^1\text{H}\}$ NMR: (121.5 MHz, CDCl_3): δ +70.9 (br.s), +109.3 (br.s). HRMS (ESI/Q-TOF) calcd for $\text{C}_{35}\text{H}_{41}\text{B}_2\text{NOP}_2\text{Na}$ $[\text{M}+\text{Na}]^+$: 598.27472; found: 598.27261. Anal. calcd for $\text{C}_{35}\text{H}_{41}\text{B}_2\text{NOP}_2$: C 73.07, H 7.18, N 2.43; found: C 72.70, H 7.28, N 2.62.

4.7.8. *(S_p)-N-[(1S,2R)-2-(Phenyl-o-tolylphosphinito-borane)-1-methyl-2-phenylethyl], N-methyl aminodiphenylphosphine-borane 21d*. This compound was synthesized as described for *(R_p)-21d* (§ 4.7.7.) starting from (-)-ephedrine **9**. X-ray quality crystals were grown by slow evaporation of hexane. The structure and the data were reported in the SI.

4.7.9. *(R_p)-(-)-N-[(1R,2S)-2-(Phenyl-p-tolylphosphinito-borane)-1-methyl-2-phenylethyl], N-methylaminodiphenylphosphine-borane 21e*. This compound was synthesized from *(R_p)-(-)-N-[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl], N-methylamino(phenyl-p-tolyl)phosphine-borane 11e* previously prepared from (+)-ephedrine **9**.³¹ X-ray quality crystals were grown by slow evaporation of diethyl ether. The structure and the data were reported in the SI. Colorless crystals (0.39 g, 67% yield); $R_f = 0.60$ (toluene); Mp = 156 °C. $[\alpha]_{\text{D}}^{20} = -71.6$ (c 0.5, CHCl_3). ^1H NMR (500 MHz, CDCl_3): δ 0.30-1.68 (m, 6H), 1.25 (d, $J = 6.5$ Hz, 3H), 2.22 (d, $J = 7.6$ Hz, 3H), 2.32 (s, 3H), 4.46-4.55 (m, 1H), 5.30 (t, $J = 9.4$ Hz, 1H), 6.52-6.58 (m, 2H), 6.97-7.11 (m, 7H), 7.15-7.24 (m, 6H), 7.28-7.35 (m, 4H), 7.37-7.42 (m, 1H), 7.43-7.49 (m, 2H), 7.51-7.56 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125.8 MHz, CDCl_3): δ 16.2,

21.6, 29.4 (d, $J = 4.5$ Hz), 57.4 (dd, $J = 11.2, 8.0$ Hz), 83.1 (dd, $J = 9.0, 2.5$ Hz), 127.8 (d, $J = 10.3$ Hz), 128.0 (d, $J = 10.4$ Hz), 128.2, 128.4 (d, $J = 10.0$ Hz), 128.4, 128.7, 129.3, 129.4 (d, $J = 11.0$ Hz), 129.7 (d, $J = 71.5$ Hz), 130.3 (d, $J = 2.3$ Hz), 130.7 (d, $J = 57.8$ Hz), 131.3 (d, $J = 11.8$ Hz), 131.2 (d, $J = 11.9$ Hz), 131.5 (d, $J = 11.7$ Hz), 131.7 (d, $J = 10.2$ Hz), 132.1 (d, $J = 59.7$ Hz), 132.5 (d, $J = 10.2$ Hz), 138.2, 142.2 (d, $J = 3.0$ Hz). $^{31}\text{P}\{^1\text{H}\}$ NMR (202.5 MHz, CDCl_3): δ +71.0 (br.s), +107.0 (br.s). HRMS (ESI/Q-TOF) calcd for $\text{C}_{35}\text{H}_{41}\text{B}_2\text{NOP}_2\text{Na}$ $[\text{M}+\text{Na}]^+$: 598.27417; found: 598.27340. Anal. calcd for $\text{C}_{35}\text{H}_{41}\text{B}_2\text{NOP}_2$: C 73.07, H 7.18, N 2.43; found: C 72.70, H 7.28, N 2.52.

4.7.10. *(R_p)-(-)-N-[(1R,2S)-2-(Phenyl-*o*-biphenylphosphinito-borane)-1-methyl-2-phenylethyl], N-methylamino-diphenylphosphine-borane 21f.* This compound was synthesized from *(R_p)-(-)-N-[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl], N-methylamino(phenyl-*o*-biphenyl)phosphine-borane 11f* previously prepared from (+)-ephedrine **9**.^{11b,29,30} X-ray quality crystals were grown by slow evaporation of CH_2Cl_2 . The structure and the data were reported in the SI. White solid; (0.43 g, 67% yield); $R_f = 0.57$ (petroleum ether/dichloromethane 1:1); Mp = 217 °C. $[\alpha]_{\text{D}}^{20} = -5.9$ (c 0.4, CHCl_3). ^1H NMR: (500 MHz, CD_2Cl_2): δ 0.48-1.52 (m, 6H), 1.29 (d, $J = 5.7$ Hz, 3H), 2.29 (d, $J = 7.6$ Hz, 3H), 4.51-4.54 (m, 1H), 5.54 (t, $J = 9.9$ Hz, 1H), 6.60-6.64 (m, 2H), 6.69-6.73 (m, 2H), 6.84-6.86 (m, 2H), 6.90-6.94 (m, 2H), 7.11-7.17 (m, 5H), 7.22-7.35 (m, 8H), 7.44-7.63 (m, 7H), 8.33

(dd, $J = 13.1, 7.2$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125.8 MHz, CD_2Cl_2): δ (ppm) 16.0, 29.2 (d, $J = 4.5$ Hz), 57.3 (dd, $J = 10.9, 7.0$ Hz), 83.6 (dd, $J = 9.5, 3.3$ Hz), 127.0 (d, $J = 12.5$ Hz), 127.1 (2s), 127.4 (d, $J = 11.1$ Hz), 128.0 (d, $J = 10.2$ Hz), 128.3, 128.4 (d, $J = 9.9$ Hz), 128.5, 128.7, 129.5, 129.8, 130.1 (d, $J = 12.5$ Hz), 130.2 (d, $J = 3.7$ Hz), 130.3 (d, $J = 2.1$ Hz), 130.5 (d, $J = 24.5$ Hz), 131.0 (d, $J = 32.0$ Hz), 131.1 (d, $J = 2.1$ Hz), 131.6 (d, $J = 10.3$ Hz), 131.7 (d, $J = 2.2$ Hz), 131.9 (d, $J = 7.7$ Hz), 132.5 (d, $J = 10.3$ Hz), 133.3 (d, $J = 63.5$ Hz), 133.5 (d, $J = 18.0$ Hz), 138.5, 140.3 (d, $J = 3.0$ Hz), 146.7 (d, $J = 5.3$ Hz). $^{31}\text{P}\{^1\text{H}\}$ NMR (202.5 MHz, CD_2Cl_2): δ +71.1 (br.s), +110.6 (br.s). IR (neat): ν_{max} 3057, 2982, 2393, 1458, 1436, 1225, 1160, 1132, 1112, 1062, 1009, 991, 965, 928, 895, 873, 758, 746, 735, 718, 697, 610 cm^{-1} . HRMS (ESI/Q-TOF) calcd for $\text{C}_{40}\text{H}_{43}\text{B}_2\text{NOP}_2\text{Na}$ $[\text{M}+\text{Na}]^+$: 660.2898; found: 660.2884. Anal. calcd for $\text{C}_{40}\text{H}_{43}\text{B}_2\text{NOP}_2$: C 75.38, H 6.80, N 2.20; found: C 75.05, H 6.80, N 2.20.

4.7.11. *(R_p)-(+) -N-[(1R,2S)-2-Ferrocenylphenylphosphinito-borane]-1-methyl-2-phenylethyl]*, *N-methylaminodiphenylphosphine-borane* **21g**. This compound was synthesized from *(R_p)-(+) -N-[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]*, *N-methylamino(ferrocenylphenyl)phosphine-borane* **11g** previously prepared from (+)-ephedrine **9**.^{11b,15,30} X-ray quality crystals were grown by slow evaporation of CH_2Cl_2 . The structure and the data were reported in the SI. Orange crystals; (0.46 g, 68% yield); $R_f =$

0.60 (toluene); Mp = 150 °C. $[\alpha]_D^{20} = +9.8$ (c 0.5, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 0.42-1.46 (m, 6H), 1.28 (d, $J = 6.6$ Hz, 3H), 2.19 (d, $J = 7.6$ Hz, 3H), 4.02 (s, 5H), 4.09 (m, 1H), 4.33 (m, 1H), 4.40 (m, 2H), 4.58 (m, 1H), 5.14 (t, $J = 9.4$ Hz, 1H), 6.52-6.58 (m, 2H), 6.95-7.05 (m, 5H), 7.07-7.18 (m, 3H), 7.15-7.17 (m, 1H), 7.19-7.24 (m, 2H), 7.29-7.33 (m, 2H), 7.36-7.40 (m, 1H), 7.42-7.49 (m, 4H). ¹³C{¹H} NMR (125.8 MHz, CDCl₃): δ 15.9, 29.4 (d, $J = 4.3$ Hz), 57.9 (dd, $J = 10.9, 8.1$ Hz), 70.0, 71.1 (d, $J = 9.6$ Hz), 71.5 (d, $J = 8.9$ Hz), 72.1 (d, $J = 7.7$ Hz), 72.2 (d, $J = 14.1$ Hz), 72.6 (d, $J = 85.3$ Hz), 82.6 (dd, $J = 8.6, 3.3$ Hz), 125.3, 127.6 (d, $J = 10.7$ Hz), 128.0 (d, $J = 10.6$ Hz), 128.0, 128.1, 128.2, 128.4 (d, $J = 10.0$ Hz), 128.6, 128.9 (d, $J = 29.0$ Hz), 129.8 (d, $J = 71.3$ Hz), 130.3 (d, $J = 2.4$ Hz), 130.7 (d, $J = 57.9$ Hz), 130.8, 131.1 (d, $J = 1.8$ Hz), 131.2 (d, $J = 2.1$ Hz), 131.3 (d, $J = 11.2$ Hz), 131.7 (d, $J = 10.2$ Hz), 131.9 (d, $J = 61.7$ Hz), 132.5 (d, $J = 10.4$ Hz), 138.3. ³¹P{¹H} NMR (202.5 MHz, CDCl₃): δ +71.7 (br.s), +106.9 (br.s). HRMS (ESI/Q-TOF) calcd for C₃₈H₄₃B₂FeNOP₂ [M]⁺: 669.2363 found: 669.2367. HRMS (ESI/Q-TOF) calcd for C₃₈H₄₃B₂FeNOP₂Na [M+Na]⁺: 692.2261; found: 692.2247. Anal. calcd for C₃₈H₄₃B₂FeNOP₂: C 68.21, H 6.48, N 2.09; found: C 68.00, H 6.49, N 2.11.

4.7.12. (*S_p*)-(-)-*N*-[(1*R*,2*S*)-2-*t*-Butylphenylphosphinito-borane]-1-methyl-2-phenylethyl],

N-methyl aminodiphenylphosphine-borane **21h**. This compound was synthesized from

(*S_p*)-(+)-*N*-[(1*R*,2*S*)-2-hydroxy-1-methyl-2-phenylethyl],

N-methylamino(*t*-

1 *butyl*)phenylphosphine-borane **11h** previously prepared from (+)-ephedrine **9**.^{11b,32} X-ray
2
3
4 quality crystals were grown by slow evaporation of hexane. The structure and the data
5
6
7 were reported in the SI. Colorless crystals; (0.32 g, 59% yield); R_f = 0.55 (toluene); Mp =
8
9
10 234 °C. $[\alpha]_D^{20}$ = -93.6 (c 1.0, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ 0.25-1.77 (m, 6H), 1.13
11
12 (d, J = 14.6 Hz, 9H), 1.51 (d, J = 6.5 Hz, 3H), 2.23 (d, J = 7.5 Hz, 3H), 4.63-4.76 (m, 1H),
13
14 5.26 (t, J = 9.5 Hz, 1H), 6.53-6.63 (m, 2H), 6.96-7.62 (m, 18H). ¹³C{¹H} NMR: (75.5 MHz,
15
16 CDCl₃): δ 16.7, 24.4 (d, J = 2.9 Hz), 29.2 (d, J = 4.8 Hz), 32.5 (d, J = 44.7 Hz), 57.1 (dd, J
17
18 = 11.1, 8.6 Hz), 82.4 (dd, J = 9.2, 5.1 Hz), 126.9 (d, J = 10.0 Hz), 128.0 (d, J = 10.8 Hz),
19
20 128.1, 128.3, 128.5 (d, J = 5.0 Hz), 128.7, 129.1, 129.3 (d, J = 6.8 Hz), 130.3 (d, J = 2,4
21
22 Hz), 130.4 (d, J = 19.2 Hz), 130.8 (d, J = 2.6 Hz), 131.1 (d, J = 2.1 Hz), 131.6 (d, J = 10.4
23
24 Hz), 132.5 (d, J = 10.1 Hz), 132.5 (d, J = 10.4 Hz), 138.2. ³¹P{¹H} NMR (121.5 MHz,
25
26 CDCl₃): δ +71.1 (br.s), +125.5 (br.s). HRMS (ESI/Q-TOF) calcd for C₃₂H₄₃B₂NOP₂Na
27
28 [M+Na]⁺: 564.28982; found: 664.28944. Anal. calcd for C₃₂H₄₃B₂NOP₂: C 71.01, H 8.01, N
29
30 2.59; found: C 70.92, H 8.39, N 2.65.

49 4.7.13. (*S_p*)-(-)-*N*-[(1*R*,2*S*), 2-(Phenyl-*o*-biphenylphosphinito-borane)-1-methyl-2-
50 phenylethyl], *N*-methylamino-diphenylphosphine-borane **21i**. This compound was
51
52 synthesized from (*S_p*)-(+)-*N*-[(1*R*,2*S*)-2-hydroxy-1-methyl-2-phenylethyl], *N*-
53
54 methylamino(phenyl-*o*-biphenyl)phosphine-borane **11i** previously prepared from (+)-
55
56
57
58
59
60

ephedrine **9**. White solid; (0.37 g, 58% yield); $R_f = 0.58$ (petroleum ether/dichloromethane 1:1); Mp = 200-202 °C. $[\alpha]_D^{20} = -67.7$ (c 0.4, CHCl₃). ¹H NMR: (500 MHz, CD₂Cl₂): δ 0.47-1.47 m, 6H), 1.25 (d, $J = 6.6$ Hz, 3H), 2.32 (d, $J = 7.7$ Hz, 3H), 4.57-4.65 (m, 1H), 5.52 (t, $J = 8.9$ Hz, 1H), 6.69-6.73 (m, 2H), 6.77-6.79 (m, 2H), 7.05-7.08 (m, 3H), 7.15-7.38 (m, 21H), 7.84 (ddd, $J = 13.5, 7.8, 1.0$ Hz, 1H). ¹³C{¹H} NMR (125.8 MHz, CD₂Cl₂): δ 16.0, 29.3 (d, $J = 4.5$ Hz), 57.2 (dd, $J = 11.4, 8.6$ Hz), 83.5 (dd, $J = 8.9, 2.5$ Hz), 126.4 (d, $J = 11.7$ Hz), 127.0 (2s), 127.9 (d, $J = 10.9$ Hz), 128.1 (d, $J = 10.9$ Hz), 128.2, 128.4 (d, $J = 10.1$ Hz), 128.7, 129.2, 129.5, 129.6, 130.2 (d, $J = 10.9$ Hz), 130.3 (d, $J = 48.4$ Hz), 130.4 (d, $J = 2.3$ Hz), 130.6 (d, $J = 2.3$ Hz), 130.9 (d, $J = 23.4$ Hz), 131.1 (d, $J = 1.6$ Hz), 131.4 (d, $J = 10.2$ Hz), 131.4, 131.7 (d, $J = 10.9$ Hz), 132.5 (d, $J = 10.2$ Hz), 133.2 (d, $J = 71.8$ Hz), 133.9 (d, $J = 17.2$ Hz), 138.0, 140.2 (d, $J = 2.5$ Hz), 146.1 (d, $J = 6.4$ Hz). ³¹P{¹H} NMR: (202.5 MHz, CD₂Cl₂): δ +71.2 (br.s), +107.7 (br.s). HRMS (ESI/Q-TOF) calcd for C₄₀H₄₄B₂NOP₂ [M+H]⁺: 638.3092; found: 638.3091.

4.8. Typical procedure for the decomplexation of aminophosphine-phosphinite-diborane

21. A solution of aminophosphine-phosphinite-diborane **21** (1 mmol) and DABCO (4 mmol) in toluene (3 mL) was heated at 50°C with an oil bath and was stirred under argon overnight. After removing the solvent under vacuum, the residue was purified by

1 chromatography on neutral aluminium-oxide using a mixture of petroleum ether/ethyl
2
3 acetate (4:1) or toluene as eluent, to afford the free AMPP* **20**.
4
5

6
7 **4.8.1.** (*R_p*)-*N*-[(1*R*,2*S*)-2-(*o*-Anisylphenylphosphinito)-1-methyl-2-phenylethyl], *N*-
8
9
10 *methylamino diphenylphosphine 20a*. 0.49 g, 87% yield; White sticky solid; *R_f* = 0.70
11
12 (petroleum ether/ethyl acetate 4:1). ¹H NMR (500 MHz, CDCl₃): δ 1.34 (d, *J* = 6.6 Hz, 3H),
13
14 2.13 (d, *J* = 3.0 Hz, 3H), 3.61 (s, 3H), 3.89-3.95 (m, 1H), 4.78 (t, *J* = 8.7 Hz, 1H), 6.56-6.59
15
16 (m, 2H), 6.72 (dd, *J* = 8.2, 4.6 Hz, 1H), 6.95-7.11 (m, 13H), 7.19-7.25 (m, 7H), 7.53 (ddd, *J*
17
18 = 7.3, 4.2, 1.6 Hz, 1H). ³¹P{¹H} NMR (202.5 MHz, CDCl₃): δ +64.9, +101.3.
19
20
21
22
23
24
25
26
27

28 **4.8.2.** (*S_p*)-*N*-[(1*S*,2*R*)-2-(*o*-Anisylphenylphosphinito)-1-methyl-2-phenylethyl], *N*-
29
30
31 *methylamino diphenylphosphine 20a*. 0.48 g, 85% yield; White sticky solid; *R_f* = 0.74
32
33 (petroleum ether/ethyl acetate 4:1). ¹H NMR (500 MHz, CDCl₃): δ 1.19 (d, *J* = 6.5 Hz, 3H),
34
35 2.10 (d, *J* = 3.1 Hz, 3H), 3.47 (s, 3H), 3.85-3.95 (m, 1H), 4.70 (t, *J* = 9.1 Hz, 1H), 6.57-6.60
36
37 (m, 2H), 6.77-6.80 (m, 1H), 6.99-7.20 (m, 13H), 7.23-7.32 (m, 7H), 7.43-7.52 (m, 1H).
38
39
40
41
42
43
44
45
46 ³¹P{¹H} NMR (202.5 MHz, CDCl₃): δ +65.2, +102.0.
47
48

49 **4.8.3.** (*R_p*)-*N*-[(1*R*,2*S*)-2-(*α*-Naphthylphenylphosphinito)-1-methyl-2-phenylethyl], *N*-
50
51
52 *methyl aminodiphenylphosphine 20b*. 0.53 g, 91% yield; White sticky solid; *R_f* = 0.70
53
54 (toluene). ¹H NMR (500 MHz, CDCl₃): δ 1.22 (d, *J* = 6.6 Hz, 3H), 2.10 (d, *J* = 3.0 Hz, 3H),
55
56 3.91-3.96 (m, 1H), 4.80 (t, *J* = 8.9 Hz, 1H), 6.56-6.59 (m, 2H), 6.97-7.21 (m, 16H), 7.30-
57
58
59
60

7.32 (m, 3H), 7.34-7.36 (m, 1H), 7.44-7.48 (m, 1H), 7.78 (dd, $J = 17.5, 8.1$ Hz, 2H), 7.92 (td, $J = 7.2, 1.1$ Hz, 1H), 8.18 (dd, $J = 2.1, 8.4$ Hz, 1H). $^{31}\text{P}\{^1\text{H}\}$ NMR (202.5 MHz, CDCl_3): δ +64.7, +107.4.

4.8.4. (S_p) - N -[(1*S*,2*R*)-2-(α -Naphthylphenylphosphinito)-1-methyl-2-phenylethyl], N -methyl aminodiphenylphosphine **20b**. $^{31}\text{P}\{^1\text{H}\}$ NMR (202.5 MHz, CDCl_3): δ +64.3, +108.4.

4.8.5. (R_p) - N -[(1*R*,2*S*)-2-(β -Naphthylphenylphosphinito)-1-methyl-2-phenylethyl], N -methyl aminodiphenylphosphine **20c**. 0.52 g, 89% yield; White sticky solid; $R_f = 0.60$ (toluene). ^1H NMR (500 MHz, CDCl_3): 1.28 (d, $J = 6.6$ Hz, 3H), 2.12 (d, $J = 3.1$ Hz, 3H), 3.89-3.99 (m, 1H), 4.76 (t, $J = 8.9$ Hz, 1H), 6.57-6.60 (m, 2H), 6.95-6.99 (m, 2H), 7.05-7.20 (m, 13H), 7.29-7.32 (m, 2H), 7.42-7.44 (m, 3H), 7.70-7.80 (m, 4H), 8.06 (d, $J = 9.9$ Hz, 1H). $^{31}\text{P}\{^1\text{H}\}$ NMR (202.5 MHz, CDCl_3): δ +64.8, +110.5.

4.8.6. (R_p) - N -[(1*R*,2*S*)-2-(Phenyl-*o*-tolylphosphinito)-1-methyl-2-phenylethyl], N -methylamino diphenylphosphine **20d**. 0.51 g, 90% yield; White sticky solid; $R_f = 0.65$ (toluene). ^1H NMR (500 MHz, CDCl_3): δ 1.31 (d, $J = 6.6$ Hz, 3H), 2.13 (d, $J = 3.1$ Hz, 3H), 2.16 (s, 3H), 3.82-3.98 (m, 1H), 4.74 (t, $J = 8.6$ Hz, 1H), 6.57-6.60 (m, 2H), 6.98-7.21 (m, 21H), 7.71-7.73 (m, 1H). $^{31}\text{P}\{^1\text{H}\}$ NMR (202.5 MHz, CDCl_3): δ +64.7, +104.7.

4.8.7. (R_p) - N -[(1*R*,2*S*)-2-(Phenyl-*p*-tolylphosphinito)-1-methyl-2-phenylethyl], N -methylamino diphenylphosphine **20e**. $^{31}\text{P}\{^1\text{H}\}$ NMR (202.5 MHz, CDCl_3): δ +64.5, +112.5.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

4.8.8. (*R_p*)-*N*-[(1*R*,2*S*)-2-(Phenyl-*o*-biphenylphosphinito)-1-methyl-2-phenylethyl], *N*-methyl amino-diphenylphosphine **20f**. 0.66 g, 94% yield; White sticky solid; *R_f* = 0.75 (petroleum ether/ ethyl acetate 4:1). ¹H NMR (300 MHz, CD₂Cl₂): δ 1.35 (d, *J* = 6.3 Hz, 3H), 2.19 (d, *J* = 3.2 Hz, 3H), 3.90-4.00 (m, 1H), 4.68 (t, *J* = 8.7 Hz, 1H), 6.65-6.70 (m, 2H), 6.98-7.03 (m, 2H), 7.07-7.15 (m, 4H), 7.16-7.27 (m, 12H), 7.28-7.35 (m, 6H), 7.42-7.52 (m, 2H), 7.90-8.00 (m, 1H). ³¹P{¹H} NMR (121.5 MHz, CD₂Cl₂): δ +64.9, + 101.9.

4.8.9. (*R_p*)-(+)-*N*-[(1*R*,2*S*)-2-Ferrocenylphenylphosphinito)-1-methyl-2-phenylethyl], *N*-methyl aminodiphenylphosphine **20g**. 0.56 g, 88% yield; Orange sticky solid; *R_f* = 0.60 (toluene). ¹H NMR (300 MHz, CDCl₃): δ 1.27 (d, *J* = 6.7 Hz, 3H), 2.13 (d, *J* = 3.2 Hz, 3H), 3.67 (m, 1H), 3.74-3.85 (m, 1H), 4.00 (s, 5H), 4.19 (m, 1H), 4.29 (m, 1H), 4.36 (m, 1H), 4.71 (t, *J* = 9.0 Hz, 1H), 6.63-6.68 (m, 2H), 7.01-7.20 (m, 16H), 7.40-7.45 (m, 2H). ³¹P{¹H} NMR (121.5 MHz, CDCl₃): δ +64.7 (s), +105.5 (s).

4.8.10. (*S_p*)-(-)-*N*-[(1*R*,2*S*)-2-*t*-Butylphenylphosphinito)-1-methyl-2-phenylethyl], *N*-methylamino diphenylphosphine **20h**. ¹P{¹H} NMR (121.5 MHz, CD₂Cl₂): δ +66.4, + 129.4.

4.8.11. (*S_p*)-*N*-[(1*R*,2*S*)-2-(Phenyl-*o*-biphenylphosphinito)-1-methyl-2-phenylethyl], *N*-methyl aminodiphenylphosphine **20i**. 0.54 g, 88% yield; White sticky solid; *R_f* = 0.74 (petroleum ether/ethyl acetate 4:1). ¹H NMR (300 MHz, CDCl₃): δ 1.15 (d, *J* = 6.8 Hz, 3H), 2.05 (d, *J* = 4.0 Hz, 3H), 3.81-3.90 (m, 1H), 4.63 (t, *J* = 8.1 Hz, 1H), 6.52-6.57 (m, 2H),

6.81-6.85 (m, 2H), 6.96-7.21 (m, 24H), 7.58-7.62 (m, 1H). $^{31}\text{P}\{^1\text{H}\}$ NMR (121.5 MHz, CDCl_3): δ +65.1, + 104.8.

4.9. Preparation of dichloropalladium-AMPP* complexes 30-32.

4.9.1. General procedure: In a Schlenk tube, under an argon atmosphere, 26.8 mg (0.104 mmol) of $\text{Pd}(\text{CH}_3\text{CN})_2\text{Cl}_2$ and 2 mL of anhydrous dichloromethane were introduced. A solution of 0.104 mmol (1 equivalent) of decomplexed AMPP (R_p)-13f, (R_p)-13g or (R_p)-20b in 3 mL of dry dichloromethane was added. The mixture was then stirred at room temperature for 15 min. The solvents were evaporated under vacuo and the crude solid was recrystallized using a mixture of CH_2Cl_2 /toluene or toluene/hexane.

4.9.2. N-[(1R,2S)-(2-(Diphenylphosphinito)-1-methyl-2-phenylethyl)], N-methylamino(o-biphenyl) phenylphosphine dichloropalladium complex 30. Recrystallization in mixture of CH_2Cl_2 /toluene; Colorless crystals; X-ray quality crystals were grown by slow evaporation of CH_2Cl_2 . The structure and the data were reported in the SI. $[\alpha]_{\text{D}}^{20} = +214$ (c 0.2, CHCl_3); $M_p = 288$ °C. ^1H NMR (400 MHz, CD_2Cl_2): δ 0.00 (d, $J = 8.0$ Hz, 3H), 1.92 (d, $J = 7.2$ Hz, 3H), 3.93 (br.s, 1H), 4.23-4.24 (m, 1H), 6.85 (dd, $J = 14.2$ Hz, 7.9 Hz, 1H), 6.96-6.98 (m, 2H), 7.15-7.35 (m, 8H), 7.46-7.73 (m, 14H), 7.92-7.96 (m, 2H), 8.14-8.56 (br.s, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100.6 MHz, CD_2Cl_2): δ 12.8 (d, $J = 6.0$ Hz), 33.9 (d, $J = 4.4$ Hz), 59.0 (t, $J = 9.9$ Hz), 82.2 (d, $J = 4.5$ Hz), 126.4 (d, $J = 11.2$ Hz), 127.2, 127.7, 127.9 (d, $J = 11.9$ Hz),

128.2 (d, $J = 9.8$ Hz), 128.5, 128.6, 128.7, 129.6, 129.8 (d, $J = 53.8$ Hz), 130.7, 131.1 (d, $J = 2.1$ Hz), 131.6 (d, $J = 45.4$ Hz), 131.6 (d, $J = 2.8$ Hz), 131.7 (d, $J = 2.1$ Hz), 132.2 (d, $J = 11.2$ Hz), 133.0 (d, $J = 2.1$ Hz), 133.1 (d, $J = 9.1$ Hz), 134.4 (d, $J = 10.2$ Hz), 134.6 (d, $J = 57.8$ Hz), 134.9 (d, $J = 12.7$ Hz), 135.1, 142.8 (d, $J = 9.3$ Hz), 143.9 (d, $J = 8.3$ Hz). $^{31}\text{P}\{^1\text{H}\}$ NMR (161.9 MHz, CD_2Cl_2): δ +95.6 (d, $J = 42.0$ Hz), +106.2 (d, $J = 42.0$ Hz). FTIR (neat): ν_{max} 3054, 2991, 2891, 2835, 1480, 1463, 1444, 1434, 1382, 1376, 1230, 1207, 1182, 1158, 1134, 1101, 1084, 1072, 1029, 1018, 996, 944, 921, 896, 841, 833, 743, 732, 712, 689, 677, 653. Anal. calcd for $\text{C}_{40}\text{H}_{37}\text{NOP}_2\text{Cl}_2\text{Pd}$, H_2O : C 59.70, H 4.88, N 1.74; found: C 59.83, H 4.82, N 2.22.

4.9.3. (R_p)-*N*-[(1*R*,2*S*)-(2-(Diphenylphosphinito)-1-methyl-2-phenylethyl)], *N*-methylamino ferrocenylphenylphosphine dichloropalladium complex **31**. Recrystallization in a mixture of toluene/hexane; orange crystals; X-ray quality crystals were grown by slow evaporation of CH_2Cl_2 . The structure and the data were reported in the SI. $[\alpha]_{\text{D}}^{20} = -177$ (c 0.5, CHCl_3); Mp = 250 °C. ^1H NMR (300 MHz, CDCl_3): δ 0.81 (d, $J = 6.8$ Hz, 3H), 2.10 (d, $J = 11.9$ Hz, 3H), 3.85 (br.s, 1H), 4.03 (s, 5H), 4.53 (s, 1H), 4.70 (s, 2H), 5.40-5.51 (m, 2H), 6.56-6.58 (m, 2H), 7.00-7.19 (m, 7H), 7.42-7.63 (m, 7H), 8.27-8.33 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75.5 MHz, CDCl_3): δ 13.7 (d, $J = 4.3$ Hz), 29.6, 33.7 (d, $J = 4.9$ Hz), 53.4, 56.8, 71.2 (d, $J = 11.8$ Hz), 71.5, 72.4 (d, $J = 67$ Hz), 72.8 (d, $J = 3.4$ Hz), 79.3-79.4 (m), 79.7, 125.2, 127.5, 127.6,

1 127.7 (d, $J = 4.8$ Hz), 127.9, 128.5 (d, $J = 11.6$ Hz), 128.6 (d, $J = 60.9$ Hz), 131.4-131.5
2
3
4 (m), 132.0 (d, $J = 2.8$ Hz), 132.0 (d, $J = 65.0$ Hz), 132.9, 133.0, 133.2, 133.8, 134.5 (d, $J =$
5
6
7 54.4 Hz), 134.6 (d, $J = 12.9$ Hz), 134.8, 136.1 (d, $J = 2.6$ Hz). $^{31}\text{P}\{^1\text{H}\}$ NMR (121.5 MHz,
8
9
10
11 CDCl_3): δ +132.0 (d, $J = 33.8$ Hz), +87.4 (d, $J = 33.8$ Hz). FTIR (neat): ν_{max} 2963, 1481,
12
13
14 1258, 1081, 1012, 791, 688.

15
16
17
18 4.9.4. (R_p) - N -[(1*R*,2*S*)-2-(α -Naphthylphenylphosphinito)-1-methyl-2-phenylethyl], N -
19
20
21 *methylamino diphenylphosphine dichloropalladium complex 32*. X-ray quality crystals were
22
23
24
25 grown by slow evaporation of CH_2Cl_2 . The structure and the data were reported in the SI;
26
27
28 Slightly yellow crystals. ^1H NMR (500 MHz, CDCl_3): δ 0.71 (d, $J = 7.1$ Hz, 3H), 1.78 (d, $J =$
29
30
31 9.7 Hz, 3H), 4.83-4.95 (m, 2H), 7.20-7.33 (m, 7H), 7.36-7.53 (m, 10H), 7.55-7.59 (m, 1H),
32
33
34 7.72-7.83 (m, 4H), 7.85-7.90 (m, 1H), 8.06-8.17 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125.8 MHz,
35
36
37 CDCl_3): δ 14.0 (d, $J = 2.8$ Hz), 33.4 (d, $J = 5.8$ Hz), 56.3 (t, $J = 8.3$ Hz), 83.7 (t, $J = 4.7$ Hz),
38
39
40
41 124.2 (d, $J = 14.4$ Hz), 126.2, 126.7, 126.8, 127.0 (d, $J = 8.4$ Hz), 128.1, 128.2, 128.6 (d, J
42
43 = 10.0 Hz), 128.6, 128.7 (d, $J = 5.3$ Hz), 129.1 (d, $J = 75.5$ Hz), 129.2, 130.0 (d, $J = 56.1$
44
45
46 Hz), 131.3 (d, $J = 2.2$ Hz), 131.6 (d, $J = 2.5$ Hz), 132.1 (d, $J = 51.2$ Hz), 132.6 (d, $J = 9.1$
47
48
49 Hz), 132.7 (d, $J = 2.0$ Hz), 132.9 (d, $J = 2.6$ Hz), 133.0 (d, $J = 11.7$ Hz), 133.3 (d, $J = 10.4$
50
51
52 Hz), 132.7 (d, $J = 2.0$ Hz), 132.9 (d, $J = 2.6$ Hz), 133.0 (d, $J = 11.7$ Hz), 133.3 (d, $J = 10.4$
53
54
55 Hz), 133.9 (d, $J = 8.7$ Hz), 134.9 (d, $J = 12.8$ Hz), 135.4 (d, $J = 12.8$ Hz), 135.4 (d, $J = 12.8$
56
57
58
59
60

Hz), 135.7 (d, $J = 7.0$ Hz). $^{31}\text{P}\{^1\text{H}\}$ NMR (202.5 MHz, CDCl_3): δ +96.8 (d, $J = 47.3$ Hz),
+116.3 (d, $J = 47.3$ Hz).

4.10. Allylic alkylation of (\pm)-1,3-diphenylpropenyl acetate **24** with dimethylmalonate or benzylamine.

4.10.1. General procedure: In a flask under argon atmosphere was introduced AMPP* ligand (0.02 or 0.04 mmol), $[\text{Pd}(\text{C}_3\text{H}_5)\text{Cl}]_2$ (0.01 or 0.02 mmol) and allylic acetate (1 mmol) in dry dichloromethane (3 mL). After stirring the solution for one hour at room temperature, dimethylmalonate or benzylamine (2 mmol) was added, followed by *N,O*-bis(trimethylsilyl)acetamide (2 mmol) and potassium acetate (10 mg) or TBAF (2 mmol), respectively. After complete reaction, the mixture was successively diluted with Et_2O (5 mL), washed with saturated NH_4Cl solution and extracted with Et_2O . The combined organic layers were dried over MgSO_4 and filtered. The solvent was removed under vacuum to afford a residue which was purified by chromatography on silica gel using a mixture of petroleum ether/ethyl acetate (5:1) as eluent, to afford the allylated products **25** or **29** as colorless oils.

4.10.2. Procedure for oxidizable ligands: In the case of oxidizable ligand such as AMPP* **13j** ($\text{R}^1 = \text{Me}$), the purification after decomplexation of the ligand by short filtration on neutral alumina led to impure compound. The palladium catalyst was prepared according

1 to a one pot procedure. First, the AMPP*(BH₃)₂ and DABCO (4 equiv.) were heated at
2
3
4 50°C in toluene with an oil bath for 12 h. After removing the solvent under vacuum, the
5
6
7 crude AMPP* ligand was then mixed with [Pd(C₃H₅)Cl]₂ in dichloromethane at room
8
9
10 temperature for 20 min and the complex was used without further purification.
11
12

13
14 **4.10.3. Dimethyl (1,3-diphenylallyl)malonate 28:** ¹H NMR (300 MHz, CDCl₃): δ 3.44 (s,
15
16 3H), 3.63), 3.88 (d, *J* = 10.9 Hz, 1H), 4.19 (dd, *J* = 10.9, 8.5 Hz, 1H), 6.25 (dd, *J* = 15.8, 8.5
17
18 Hz, 1H), 6.41 (d, *J* = 15.8 Hz, 1H), 7.09-7.28 (m, 10H). ¹³C{¹H} NMR (75 MHz, CDCl₃): δ
19
20 49.2, 52.5, 52.7, 57.7, 126.4, 127.2, 127.6, 127.9, 128.5, 128.7, 129.1, 131.9, 136.8, 140.2,
21
22 167.8, 168.2. The enantiomeric excess was determined by HPLC analysis on Chiralpack
23
24 IA, 1.00 mL/min, hexane/isopropanol (9:1), *t*(*R*) = 8.5 min, *t*(*S*) = 10.4 min. The absolute
25
26 configuration could also be determined by comparison of the optical rotation to literature
27
28 value: [α]_D²⁵ = -22.4 (c 1.8, CHCl₃) for (*S*)-enantiomer.³⁵
29
30
31
32
33
34
35
36
37
38
39
40
41

42 **4.10.4. *N*-(1,3-Diphenylallyl),*N*-benzylamine 29:** ¹H NMR (500 MHz, CDCl₃): δ 3.79-3.87
43
44 (m, 2H), 4.45 (d, *J* = 7.5 Hz, 1H), 6.38 (dd, *J* = 15.8, 7.5 Hz, 1H), 6.61 (d, *J* = 15.8 Hz, 1H),
45
46 7.21-7.26 (m, 1H), 7.28-7.34 (m, 4H), 7.36-7.42 (m, 8H), 7.44-7.51 (m, 2H). ¹³C{¹H} NMR
47
48 (125 MHz, CDCl₃): δ 51.4, 64.6, 126.4, 127.0, 127.3, 127.4, 127.5, 128.2, 128.5, 128.5,
49
50 128.7, 130.4, 132.7, 137.0, 140.5, 142.9. The enantiomeric excess was determined by
51
52
53
54
55
56
57
58
59
60

1 HPLC analysis on Lux 5 μ m cellulose-1, 0.5 mL/min, hexane/isopropanol (98:2), t(*R*)= 20.9
2
3
4 min, t(*S*) = 22.2 min.
5
6
7
8
9

10 ASSOCIATED CONTENT

11 Supporting Information

12
13
14
15
16
17 ¹H, ¹³C{¹H}, ³¹P{¹H} NMR spectra, X-ray structures with crystallographic data, HPLC
18 chromatograms on chiral column, catalysis complementary results and computational calculations
19 are reported in part A, B and C, respectively. This material is available free of charge via the
20 internet at <http://pubs.acs.org>.
21
22
23
24
25
26
27
28
29

30 AUTHOR INFORMATION

31 Corresponding Authors

32
33
34
35
36
37 * E-mail: Sylvain.Juge@u-bourgogne.fr
38
39
40
41

42 Present Address

43
44
45
46 § Oril Industrie, 76210- Bolbec- France
47
48

49 δ RTP France, ZI Beaune-Vignolles 21207- Beaune Cedex- France
50
51
52

53 **Note:** This work is the subject in part of the patent C-bulky P-chirogenic organophosphorus
54 compounds WO 2019/180084 (2019 sept. 26th).
55
56
57
58
59
60

ACKNOWLEDGMENTS

The authors are grateful for A.J. fellowship and financial support provided by the "Ministère de l'éducation nationale de l'enseignement supérieur et de la recherche", the "Conseil régional de Bourgogne" (research programs 3MIM, PARI santé, CD2A), the Satt-SAYENS, the CNRS (Centre National de la Recherche Scientifique) and the FEDER (Fond Européen de Développement Régional). The authors would like also to thank Ms. M. J. Penouilh, F. Chaux, Mrs M. Picquet, Q. Bonin and E. Closier at the Satt-Sayens for spectroscopy analyses and valuation, Ms E. Pousson and M. M. Soustelle for the elemental analyses, M P. Richard for X-ray structures, Ms N. Khiri-Meribout, M. J. Eymin and M. M. Lagrelette, D. Moulin, P. Rasque and J. Rey for synthesis. PDH acknowledges the Natural Science and Engineering Research Council of Canada for funding. Ms L. Qin at the University of New South Wales, Australia, is warmly thanked for his help to the preparation of this manuscript.

REFERENCE

(1) (a) *Comprehensive Asymmetric Catalysis*, Jacobsen, E. N., Pfaltz, A., Yamamoto, H., Eds.; Springer: New York, 1999; Vols. I–III, Suppl. I–II (2004). (b) *Phosphorus Ligands in Asymmetric Catalysis: Synthesis and Applications*, Börner, A., Ed.; Wiley-VCH: Weinheim,

Germany, 2008; Vol 1-3. (c) *Phosphorus (III) Ligands in Homogeneous Catalysis: Design and Synthesis*, Kamer, P. C. J., van Leeuwen, P. W. N. M., Eds, Wiley, Chichester, U.K., 2012.

(2) *Comprehensive Chirality*, Carreira, E. M., Yamamoto, H., Eds.; Elsevier Science: Amsterdam, 2012; Vols. 1–9.

(3) (a) Denmark, S. E.; Beutner, G. L. Lewis base catalysis in organic synthesis. *Angew. Chem. Int. Ed.* **2008**, *47*, 1560-1638. (b) Werner, T. Phosphonium Salt Organocatalysis. *Adv. Synth. Catal.* **2009**, *351*, 1469-1481. (c) Enders, D.; Nguyen, T. V. Chiral quaternary phosphonium salts: a new class of organocatalysts. *Org. Biomol. Chem.* **2012**, *10*, 5327-5331. (d) Li, X.; Song, Q. Recent advances in asymmetric catalyzed by chiral phosphoric acids. *Chin. Chem. Lett.* **2018**, *29*, 1181-1192. (e) Ni, H.; Chan, W.-L.; Lu, X. Phosphine-catalyzed asymmetric organic reactions. *Chem. Rev.* **2018**, *118*, 9344-9411.

(4) (a) *P-Stereogenic ligands in enantioselective catalysis*, Grabulosa, A., Ed.; RSC Catalysis Series, Cambridge, U.K., 2011. (b) Kolodiazhnyi, O. I.; Kukhar, V. P.; Kolodiazhna, A. O. Asymmetric catalysis as a method for the synthesis of chiral organophosphorus compounds. *Tetrahedron: Asymmetry* **2014**, *25*, 865-922. (c) Dutartre, M.; Bayardon, J.; Jugé, S. Applications and stereoselective syntheses of P-chirogenic phosphorus compounds. *Chem. Soc. Rev.* **2016**, *45*, 5771-5794.

(5) (a) Takizawa, S.; Rémond, E.; Arteaga Arteaga, F.; Yoshida, Y.; Sridharan, V.; Bayardon, J.; Jugé, S.; Sasai, H. P-chirogenic organocatalysts: application to the aza-Morita-Baylis-Hillman (aza-MBH) reaction of ketimines. *Chem. Commun.* **2013**, *49*, 8392-8394. (b) Rémond, E.; Jugé, S. P-chirogenic organophosphorus acid-bases in asymmetric organocatalysis. *Chemistry Today* **2014**, *32*, 49-55. (c) Uruguchi, D.; Sasaki, H.; Kimura, Y.; Ito, T.; Ooi, T. Molecular design, synthesis, and asymmetric catalysis of a hexacoordinated chiral phosphate ion. *J. Am. Chem. Soc.* **2018**, *140*, 2765-2768. (d) Uruguchi, D.; Shibazaki, R.; Tanaka, N.; Yamada, K.; Yoshioka, K.; Ooi, T. Catalyst-enabled site-divergent stereoselective Michael reactions: overriding intrinsic reactivity of enynyl carbonyl acceptors. *Angew. Chem. Int. Ed.* **2018**, *57*, 4732-4736. (e) Uruguchi, D.; Yamada, K.; Sato, M.; Ooi, T. Catalyst-directed guidance of sulfur-substituted enediolates to stereoselective carbon-carbon bond formation with aldehydes. *J. Am. Chem. Soc.* **2018**, *140*, 5110-5117. (f) Aillard, P.; Gicquel, M.; Yavari, K.; Retailleau, P.; Voituriez, A.; Marinetti, A. Tuning the structure of phosphahelicenes for targeted applications in enantioselective phosphine organocatalysis. *Eur. J. Org. Chem.* **2018**, 5853-5860. (g) Yang, X.-H.; Li, J.-P.; Wang, D.-C.; Xie, M.-S.; Qu, G.-R.; Guo H.-M. Enantioselective dearomatic [3+2] cycloaddition of 2-nitrobenzofurans with aldehyde-derived Morita-Baylis-Hillman carbonates. *Chem. Commun.* **2019**, *55*, 9144-9147.

1 (6) (a) Agbossou, F.; Carpentier, J.-F.; Hapiot, F.; Suisse, I.; Mortreux, A. The amino-
2 phosphine-phosphinites and related ligands: synthesis, coordination chemistry and
3
4 phosphine-phosphinites and related ligands: synthesis, coordination chemistry and
5
6
7 enantioselective catalysis. *Coord. Chem. Rev.* **1998**, *178-180*, 1615-1645. (b) Agbossou-
8
9
10 Niedercorn, F.; Suisse, I. Chiral aminophosphine phosphinite ligands and related
11
12 auxiliaries. Recent advances in their design, coordination chemistry, and use in
13
14 enantioselective catalysis. *Coord. Chem. Rev.* **2003**, *242*, 145-158. (c) Agbossou, F. Chiral
15
16 Aminophosphine-Phosphinites (AMPP) in Phosphorus Ligands *in Asymmetric Catalysis:*
17
18 *Synthesis and Applications*, Börner, A., Ed.; Wiley-VCH: Weinheim, Germany, 2008; Vol 2,
19
20
21
22
23
24
25
26
27
28
29 pp 477-505.

30
31 (7) (a) Buono, G.; Siv, C.; Peiffer, G.; Triantaphyldes, C.; Denis, P.; Mortreux, A.; Petit, F.
32
33 Threophos: A new chiral aminophosphine phosphinite (AMPP) ligand highly efficient in
34
35 asymmetric hydrovinylation of cyclohexa-1,3-diene catalyzed by Nickel complexes. *J. Org.*
36
37
38
39
40
41
42
43 *Chem.* **1985**, *50*, 1782-1784. (b) Pardigon, O.; Buono, G. Enantioselective synthesis of
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

(7) (a) Buono, G.; Siv, C.; Peiffer, G.; Triantaphyldes, C.; Denis, P.; Mortreux, A.; Petit, F.
Threophos: A new chiral aminophosphine phosphinite (AMPP) ligand highly efficient in
asymmetric hydrovinylation of cyclohexa-1,3-diene catalyzed by Nickel complexes. *J. Org.*
Chem. **1985**, *50*, 1782-1784. (b) Pardigon, O.; Buono, G. Enantioselective synthesis of
deltacyclenes using a [Co]₂:Zn catalytic system. *Tetrahedron: Asymmetry* **1993**, *4*, 1977-
1980. (c) Pardigon, O.; Tenaglia, A.; Buono, G. Enantioselective syntheses of
monofunctionalized deltacyclenes using a [Co]₂:Zn catalytic system. *J. Org. Chem.* **1995**,
60, 1868-1871. (d) Krause, H. W.; Schmidt, U.; Taudien, S.; Costisella, B.; Michalik, M.
Aminophosphine phosphinites of propranolol analogues as ligands for Rh-catalyzed

1 asymmetric hydrogenation. *J. Mol. Cat. A* **1995**, *104*, 147-157. (e) Lou, R.; Mi, A.; Jiang,
2
3
4 Y.; Qin, Y.; Li, Z.; Fu, F.; Chan, A. S. C. Aminophosphine phosphinites derived from chiral
5
6
7 1,2-diphenyl-2-aminoethanols: synthesis and application in rhodium-catalyzed asymmetric
8
9
10 hydrogenation of dehydroamino acid derivatives. *Tetrahedron* **2000**, *56*, 5857-5863. (f) Xie,
11
12
13 Y.; Lou, R.; Li, Z.; Mi, A.; Jiang, Y. DPAMPP in catalytic asymmetric reactions:
14
15 enantioselective synthesis of L-homophenylalanine. *Tetrahedron: Asymmetry* **2000**, *11*,
16
17
18 1487-1494. (g) Pasquier, C.; Naili, S.; Mortreux, A.; Agbossou, F.; Péliniski, L.; Brocard, J.;
19
20
21 Eilers, J.; Reiners, I.; Peper, V.; Martens, Free and Cr(CO)₃-complexed aminophosphine
22
23
24 phosphinite ligands for highly enantioselective hydrogenation of α -functionalized ketones.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(8) (a) Petit, M.; Mortreux, A.; Petit, F.; Buono, G.; Peiffer, G. Préparation
d'aminophosphine-phosphinites chiraux. Applications en catalyse homogène asymétrique.
New. J. Chem. **1983**, *7*, 593-596. (b) Pracejus, G.; Pracejus, H. Chiral *O,N*-

1 bis(diphenylphosphino)aminoalkanols as ligands for enantioselective metal complex
2
3
4 hydrogenation catalysts. *J. Mol. Cat.* **1984**, *24*, 227-230. (c) Mutez, S.; Mortreux, A.; Petit,
5
6
7 F. Asymmetric hydroformylation of styrene on aminophosphinephosphinites modified
8
9
10 platinum catalysts. *Tetrahedron Lett.* **1988**, *29*, 1911-1914. (d) Potier, Y.; Mortreux, A.;
11
12
13 Petit, F. Utilisation des ligands aminophosphinephosphinites en hydroformylation catalysée
14
15
16 par le rhodium: amélioration de l'énantioselectivité par synthèse selective des hydrures
17
18
19 $RhH(CO)_2L^*_2$. *J. Organomet. Chem.* **1989**, *370*, 333-342. (e) Kokel, N.; Mortreux, A.; Petit,
20
21
22
23 F. Asymmetric hydrosilylation of a Schiff base of acetophenone catalyzed by Rh(AMPP)
24
25
26 complexes. *J. Mol. Cat.* **1989**, *57*, L5-L7. (f) Gong, L.; Chen, G.; Mi, A.; Jiang, Y.; Fu, F.;
27
28
29 Cui, X.; Chan, A. S. C. Chiral aminophosphine phosphinite-palladium catalysts in
30
31
32 asymmetric allylic alkylations. *Tetrahedron: Asymmetry* **2000**, *11*, 4297-4302.
33
34
35
36
37
38
39 (9) (a) Moulin, D.; Darcel, C.; Jugé, S. Versatile synthesis of P-chiral (ephedrine) AMPP
40
41
42 ligand *via* their borane complexes. Structural consequences in Rh-catalyzed hydrogenation
43
44
45 of methyl α -acetamidocinnamate. *Tetrahedron: Asymmetry* **1999**, *10*, 4729-4743. (b)
46
47
48
49 Darcel, C.; Moulin, D.; Henry, J.-C.; Lagrelette, M.; Richard, P.; Harvey, P. D.; Jugé, S.
50
51
52 Modular P-chirogenic aminophosphane-phosphinite ligands for Rh-catalyzed asymmetric
53
54
55 hydrogenation: A new model for prediction of enantioselectivity. *Eur. J. Org. Chem.* **2007**,
56
57
58
59 2078-2090. (c) Khiri, N.; Bertrand, E.; Ondel-Eymin, M.-J.; Rousselin, Y.; Bayardon, J.;
60

1 Harvet, P. D.; Jugé, S. Enantioselective hydrogenation catalysis aided by a σ -bonded
2
3 calix[4]arene to a P-chirogenic aminophosphane phosphinite rhodium complex.
4
5

6
7 *Organometallics* **2010**, *29*, 3622-3631.
8
9

10
11 (10) (a) Ewalds, R.; Eggeling, E. B.; Hewat, A. C.; Kramer, P. C. J.; van Leeuwen, P. W.
12
13 N. M.; Vogt, D. Application of P-stereogenic aminophosphine phosphinite ligands in
14
15 asymmetric hydroformylation. *Chem. Eur. J.* **2000**, *6*, 1496-1504. (b) Carbo, J.J.; Lledos,
16
17 A.; Vogt, D.; Bo, C. Origin of stereoiduction by chiral aminophosphane phosphinite
18
19 ligands in enantioselective catalysis: asymmetric hydroformylation. *Chem. Eur. J.* **2006**,
20
21 *12*, 1457-1467.
22
23
24
25
26
27
28
29
30

31
32 (11) (a) Bertrand, C.; Humbel, S.; Bauduin, C.; Darcel, C.; Jugé, S. Configurational
33
34 stability of chlorophosphines. *Inorg. Chem.* **2003**, *42*, 420-427. (b) Bauduin, C.; Moulin, D.;
35
36 Kaloun, E. B.; Darcel, C.; Jugé, S. Highly enantiomerically enriched chlorophosphine
37
38 boranes: synthesis and applications as P-chirogenic electrophilic blocks. *J. Org. Chem.*
39
40 **2003**, 4293-4301.
41
42
43
44
45
46
47
48

49 (12) Jaillet, A.; Bayardon, J.; Jugé, S., C-bulky P-chirogenic organophosphorus
50
51 compounds. *Intern. Patent.* EP 18305304 (2018 March 20th); PCT/EP2019/056965 (2019
52
53 March 20th); WO 2019/180084 (2019 Sept. 26th).
54
55
56
57
58
59
60

1 (13) For a representative example of diastereoselective synthesis with dynamic
2
3
4 resolution of binaphthylithium reagent, see: Clayden, J; Kubinski, P. M.; Sammicelli, F.;
5
6
7 Heliwell, M.; Diorazio, L. Sulfoxides as 'traceless' resolving agents for the synthesis of
8
9
10 atropoisomers by dynamic or classical resolution. *Tetrahedron* **2004**, *60*, 4387-4397.
11
12

13
14 (14) den Heeten, R.; Swennenhuis, B. H. G.; van Leeuwen, P. W. N. M.; de Vries, J. G.;
15
16
17 Kamer, P. C. J. Parallel synthesis and screening of polymer-supported phosphorus-
18
19
20 stereogenic aminophosphane–phosphite and -phosphinite ligands. *Angew. Chem. Int. Ed.*
21
22
23
24
25 **2008**, *47*, 6602-6605.
26
27

28 (15) Chaux, F.; Frynas, S.; Laureano, H.; Salomon, C.; Morata, G.; Auclair, M.-L.;
29
30
31 Stephan, M.; Merdès, R.; Richard, P.; Eymin, M.-J.; Henry, J.-C.; Bayardon, J.; Darcel, C.;
32
33
34
35 Jugé, S. Enantiodivergent synthesis of P-chirogenic phosphines. *C.R. Chimie* **2010**, *13*,
36
37
38
39 1213-1226.
40
41

42 (16) (a) Trost, B. M.; Crawley, M. L. Asymmetric transition-metal-catalyzed allylic
43
44
45 alkylations: Applications in total synthesis. *Chem. Rev.* **2003**, *103*, 2921-2943. (b) Trost, B.
46
47
48 M.; Zhang, T.; Sieber, J. D. Catalytic asymmetric allylic alkylation employing heteroatom
49
50
51 nucleophiles: a powerful method for C-X bond formation. *Chem. Sci.* **2010**, *1*, 427-440. (c)
52
53
54
55
56 Guerrero Rios, I.; Rosas-Hernandez, A.; Martin, E. Recent advances in the application of
57
58
59 chiral phosphine ligands in Pd-catalysed asymmetric allylic alkylation. *Molecules* **2011**, *16*,
60

1 970-1010. (d) Trost, B. M. Pd- and Mo-catalyzed asymmetric allylic alkylation. *Org.*
2
3
4 *Process Res. Dev.* **2012**, *16*, 185-194. (e) Ding, C.-H.; Hou, X. L. Nucleophiles with Allyl
5
6
7 Metal Complexes in *Comprehensive Organic Synthesis II*, Knochel, P., Molander, G. A. Eds,
8
9
10 2014, Vol. 4, pp 649-694, Elsevier. (f) Trost, B. M.; Schultz, J. E. Palladium-catalyzed
11
12
13
14 asymmetric allylic alkylation strategies for the synthesis of acyclic tetrasubstituted
15
16
17
18 stereocenters. *Synthesis* **2019**, 1-30.

19
20
21 (17) For recent applications of palladium-catalyzed asymmetric allylic alkylation in
22
23
24
25 organic synthesis, see: (a) Fournier, J.; Lozano, O.; Menozzi, C.; Arseniyadis, S.; Cossy, J.
26
27
28 Palladium-catalyzed asymmetric allylic alkylation of cyclic dienol carbonates: efficient route
29
30
31 to enantioenriched γ -butenolides bearing an all-carbon α -quaternary stereogenic center.
32
33
34
35 *Angew. Chem. Int. Ed.* **2013**, *52*, 1257-1261. (b) Lei, B.-L.; Zhang, Q.-S.; Yu, W.-H.; Ding,
36
37
38 Q.-P.; Ding, C.-H.; Hou, X.-L. Kinetic resolution of 2-substituted 2,3-dihydro-4-pyridones by
39
40
41
42 palladium-catalyzed asymmetric allylic alkylation: catalytic asymmetric total synthesis of
43
44
45
46 Indolizidine (-)-209I. *Org. Lett.* **2014**, *16*, 1944-1947. (c) Jiang, Y.-J.; Zhang, G.-P.; Huang,
47
48
49 J.-Q.; Chen, D.; Ding, C.-H.; Hou, X.-L. Palladium-catalyzed asymmetric allylic alkylation of
50
51
52
53 alkyl-substituted allyl reagents with acyclic amides. *Org. Lett.* **2017**, *19*, 5932-5935. (d) de
54
55
56
57 Oliveira, M.N.; Arseniyadis, S.; Cossy, J. Palladium-catalyzed asymmetric allylic alkylation
58
59
60 of 4-substituted isoxazolidin-5-ones: Straightforward access to $\beta^{2,2}$ -amino acids. *Chem.*

1 *Eur. J.* **2018**, *24*, 4810-4814. (e) Trost, B.M.; Bai, W.-J.; Hohn, C.; Bai, Y.; Cregg, J.J.

2
3
4 Palladium-catalyzed asymmetric allylic alkylation of 3-substituted 1*H*-indoles and
5
6
7 tryptophan derivatives with vinylcyclopropanes. *J. Am. Chem. Soc.* **2018**, *140*, 6710-6717.

8
9
10
11 (f) Song, T.; Arseniyadis, S.; Cossy, J. Asymmetric synthesis of α -quaternary γ -lactams
12
13
14 through palladium-catalyzed asymmetric allylic alkylation. *Org. Lett.* **2019**, *21*, 603-607.

15
16
17
18 (18) Nettekoven, U.; Widhalm, M.; Kalchhauser, H.; Kamer, P. C. J.; van Leeuwen, P. W.
19
20
21 N. M.; Lutz, M.; Spek, A. L. Steric and electronic ligand perturbations in catalysis:
22
23
24 asymmetric allylic substitution reactions using C_2 -symmetrical phosphorus-chiral
25
26
27
28 (bi)ferrocenyl donors. *J. Org. Chem.* **2001**, *66*, 759-770.

29
30
31
32 (19) Oohara, N.; Katagiri, K.; Imamoto, T. A novel P-chirogenic phosphine ligand, (*S,S*)-
33
34
35 1,2-bis-[(ferrocenyl)methylphosphino]ethane: synthesis and use in rhodium-catalyzed
36
37
38 asymmetric hydrogenation and palladium-catalyzed asymmetric allylic alkylation.
39
40
41
42 *Tetrahedron: Asymmetry* **2003**, *14*, 2171-2175.

43
44
45
46 (20) (a) Tsuruta, H.; Imamoto, T. P-Chirogenic monodentate phosphine ligands bearing
47
48
49 2-biphenyl group. *Synlett* **2001**, 999-1002. (b) Imamoto, T.; Nishimura, M.; Koide, A.;
50
51
52 Yoshida, K. *t*-Bu-QuinoxP* ligand: Applications in asymmetric Pd-catalyzed allylic
53
54
55 substitution and Ru-catalyzed hydrogenation. *J. Org. Chem.* **2007**, *72*, 7413-7416.
56
57
58
59
60

1 (21) Bayardon, J.; Maronnat, M.; Langlois, A.; Rousselin, Y.; Harvey, P. D.; Jugé, S.

2
3
4 Modular P-chirogenic phosphine-sulfide ligands: Clear evidence for both electronic effect
5
6
7 and P-chirality driving enantioselectivity in Palladium-catalyzed allylations. *Organometallics*
8
9
10
11 **2015**, *34*, 4340-4358.

12
13
14 (22) (a) Zhang, K.; Peng, Q.; Hou, X.-L.; Wu, Y.-D. Highly enantioselective palladium-
15
16
17 catalyzed alkylation of acyclic amides. *Angew. Chem. Int. Ed.* **2008**, *47*, 1741-1744. (b) Lei,
18
19
20 B.-L.; Ding, C.-H.; Yang, X.-F.; Wan, X.-L.; Hou, X.-L. Kinetic resolution of 2,3-dihydro-2-
21
22
23 substituted 4-quinolones by palladium-catalyzed asymmetric allylic alkylation. *J. Am.*
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Hou, X.-L. Desymmetrization of bicyclo[3.*n*.1]-3-one derivatives by palladium-catalyzed
asymmetric allylic alkylation. *Org. Lett.* **2013**, *15*, 3880-3883. (d) Yang, X.-F.; Yu, W.-H.;
Ding, C.-H.; Ding, Q.-P.; Wan, S.-L.; Hou, X.-L.; Dai, L.-X.; Wang, P.-J. Palladium-
catalyzed regio-, diastereo-, and enantioselective allylation of nitroalkanes with
monosubstituted allylic substrates. *J. Org. Chem.* **2013**, *78*, 6503-6509. (e) Bai, C.-H.; Liu,
X.-Y.; Li, H.; Ding, C.-H.; Hou, X.-L. Tandem Thorpe reaction/palladium catalyzed
asymmetric allylic alkylation: access to chiral β -enaminonitriles with excellent
enantioselectivity. *Chem. Asian J.* **2017**, *12*, 212-215.

1 (23) For a recent review on stereodivergent catalysis, see: Beletskaya, I. P.; Najera, C.;

2
3
4 Yus, M. Stereodivergent catalysis. *Chem. Rev.* **2018**, *118*, 5080-5200.

5
6
7 (24) Haquette, P.; Lebideau, F.; Dagonne, S.; Marrot, J.; Jaouen, G. A new optically pure
8
9
10 half-sandwich Cp-Ru diphosphine complex with a chiral metal centre, (*S*)-Ru(η^5 -C₅H₅)-
11
12 (EPHOS)Cl {EPHOS is (+)-(1*R*,2*S*)-2-[(diphenylphosphino)methylamino]-1-
13
14 phenylpropyldiphenyl phosphinite} *Acta Cryst.* **2002**, *C58*, m551-m552.
15
16
17
18
19
20

21 (25) (a) Cesarotti, E.; Grassi, M.; Prati, L., Demartin, F. Dynamic behaviour and X-ray
22
23 analysis of chiral η^3 -allylpalladium complexes. *J. Organomet. Chem.* **1989**, *370*, 407-419.
24
25
26
27

28 (b) Cesarotti, E.; Grassi, M.; Prati, L.; Demartin, F. Nuclear Magnetic Resonance and
29
30 Crystallographic Studies of Chiral η^3 -Allyl Palladium(II) Complexes and Asymmetric Allylic
31
32 Alkylation of Propen-2-yl Acetates. *J. Chem. Soc., Dalton Trans.* **1991**, 2073-2082.
33
34
35
36
37

38 (26) For least influence of Fukui constants in Pd-catalyzed asymmetric allylic alkylation,
39
40 see: Marinho, V. R.; Prates Ramalho, J. P.; Rodrigues, A. I.; Burke, A. J. A comparison of
41
42 (*R,R*)-Me-DUPHOS and (*R,R*)DUPHOS-*Pr* ligands in the Pd⁰-catalysed asymmetric allylic
43
44 alkylation reaction: Stereochemical and kinetic considerations. *Eur. J. Org. Chem.* **2009**,
45
46
47
48
49
50
51
52
53 6311-6317.
54
55

56 (27) (a) Mangas-Sanchez, J.; Busto, E.; Gotor-Fernandez, V.; Gotor, V. Straightforward
57
58 synthesis of enantiopure 2,3-dihydrobenzofurans by a sequential stereoselective
59
60

1 biotransformation and chemical intramolecular cyclization. *Org. Lett.* **2010**, *12*, 3498-3501.

2
3
4 (b) Reitz, A. B.; Baxter, E. W.; Codd, E. E.; Davis, C. B.; Jordan, A. D.; Maryanoff, B. E.;

5
6
7 Maryanoff, C. A.; McDonnell, M. E.; Powell, E. T.; Renzi, M. J.; Schott, M. R.; Scott, M. K.;

8
9
10 Shank, R. P.; Vaught, J. L. Orally active benzamide antipsychotic agents with affinity for

11
12
13 dopamine D₂, serotonin 5-HT_{1A}, and adrenergic α_1 receptors. *J. Med. Chem.* **1998**, *41*,

14
15
16 1997-2009. (c) Ukwitegetse, N.; Saris, P. J. G.; Sommer, J. R.; Haiges, R. M.; Djurovich, P.

17
18
19 I.; Thompson, M. E. Tetra-aza-pentacenes by means of a one-pot Friedländer synthesis.

20
21
22
23
24
25 *Chem. Eur. J.* **2019**, *25*, 1472-1475.

26
27
28 (28) Diemer, V.; Begaud, M.; Leroux, F. R.; Colobert, F. Regioselectivity in the aryne

29
30
31 cross-coupling of aryllithiums with functionalized 1,2-dibromobenzenes. *Eur. J. Org. Chem.*

32
33
34
35
36 **2011**, 341-354.

37
38
39 (29) (a) Maienza, F.; Wörle, M.; Steffanut, P.; Mezzetti, A.; Spindler, F. Ferrocenyl

40
41
42 diphosphines containing stereogenic phosphorus atoms. Synthesis and application in the

43
44
45 rhodium-catalyzed asymmetric hydrogenation. *Organometallics* **1999**, *18*, 1041-1049. (b)

46
47
48 Nettekoven, U.; Kamer, P. C. J.; van Leeuwen, P. W. N. M.; Widhalm, M.; Spek, A. L.; Lutz,

49
50
51 M. Phosphorus-chiral analogues of 1,1'-bis(diphenylphosphino)ferrocene: asymmetric

52
53
54 synthesis and application in highly enantioselective rhodium-catalyzed hydrogenation

55
56
57
58
59
60 reactions. *J. Org. Chem.* **1999**, *64*, 3996-4004.

1 (30) Colby, E. A.; Jamison, T. F. *P*-Chiral, monodentate ferrocenyl phosphines, novel
2
3
4 ligands for asymmetric catalysis. *J. Org. Chem.* **2003**, *68*, 156-166.
5
6

7 (31) Holz, J.; Rumpel, K.; Spannenberg, A.; Paciello, R.; Jiao, H.; Börner, A.
8
9
10 *P*-Chirogenic Xantphos Ligands and related ether diphosphines: Synthesis and application
11
12 in rhodium-catalyzed asymmetric hydrogenation. *ACS Catal.* **2017**, *7*, 6162-6169.
13
14
15

16 (32) Rippert, A. J.; Linden, A.; Hansen, H.-J. Formation of diastereomerically pure
17
18 oxazaphospholes and their reaction to chiral phosphane-borane adducts. *Helv. Chim. Acta*
19
20
21
22
23
24
25 **2000**, *83*, 311-321.
26

27 (33) Bayardon, J.; Rousselin, Y.; Jugé, S. Designing *P*-chirogenic 1,2-
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
diphosphinobenzenes at both *P*-centers using *P*(III)-phosphinites. *Org. Lett.* **2016**, *18*,
2930-2933.

(34) Grabulosa, A.; Mannu, A.; Muller, G.; Calvet, T.; Font-Bardia, M. *P*-Stereogenic
monophosphines in Pd-catalyzed enantioselective hydrovinylation of styrene. *J.*
Organomet. Chem. **2011**, *696*, 2338-2345. (b) Mohar, B.; Cusak, A.; Modéc, B.; Stephan,
M. *P*-Stereogenic phospholanes or phosphorinanes from *o*-biarylphosphines: Two
bridges not too far. *J. Org. Chem.* **2013**, *78*, 4665-4673.

1 (35) Sprinz, J.; Helmchen, G. Phosphinoaryl- and phosphinoalkyloxazolines as new
2
3
4 chiral ligands for enantioselective catalysis: Very high enantioselectivity in palladium
5
6
7 catalyzed allylic substitutions. *Tetrahedron Lett.* **1993**, *34*, 1769-1772.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60